EP0579766A1 - N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders - Google Patents

N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders

Info

Publication number
EP0579766A1
EP0579766A1 EP92911354A EP92911354A EP0579766A1 EP 0579766 A1 EP0579766 A1 EP 0579766A1 EP 92911354 A EP92911354 A EP 92911354A EP 92911354 A EP92911354 A EP 92911354A EP 0579766 A1 EP0579766 A1 EP 0579766A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
methyl
butyl
imidazol
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92911354A
Other languages
German (de)
French (fr)
Other versions
EP0579766B1 (en
Inventor
David B. Reitz
Robert E. Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of EP0579766A1 publication Critical patent/EP0579766A1/en
Application granted granted Critical
Publication of EP0579766B1 publication Critical patent/EP0579766B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • Non-peptidic N-arylheteroarylalkyl imidazol-2-one compounds are described for use in treatment of circulatory disorders such as hypertension and congestive heart failure.
  • angiotensin II antagonist compounds provided by an imidazol-2-one having a arylheteroarylmethyl moiety attached to a nitrogen atom of the imidazol-2-one.
  • the renin-angiotensin system is one of the hormonal mechanisms involved in regulation of
  • angiotensin II the primary active species of this system.
  • This octapeptide, angiotensin II is a potent
  • vasoconstrictor agent and also produces other physiological effects such as promoting aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, increasing vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems.
  • antagonizing angiotensin II at its receptors is a viable approach to inhibit the renin-angiotensin system, given the pivotal role of this octapeptide which mediates the actions of the renin-angiotensin system through interaction with various tissue receptors.
  • angiotensin II antagonists most of which are peptidic in nature. Such peptidic compounds are of limited use due to their lack of oral bioavailability or their short duration of action.
  • commercially-available peptidic angiotensin II antagonists e.g., Saralasin
  • Non-peptidic compounds with angiotensin II antagonist properties are known.
  • the sodium salt of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5- acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [P. C. Wong et al, J. Pharmacol. Exp. Ther., 241(1), 1-7 (1988)].
  • the sodium salt of 2-butyl-4-chloro-1-(2-nitrobenzyl)imidazole-5-acetic acid has specific
  • U.S. Patent No. 4,880,804 to Carini et al describes a family of
  • biphenylmethylbenzimidazole compounds as angiotensin II receptor blockers for use in treatment of hypertension and congestive heart failure.
  • EP #283,310 published 18 March 1987 describes a family of N 1 -diarylmethyl-N 2 -aminoalkyl-diaza-heterocyclic
  • a class of N-substituted arylheteroarylalkyl imidazol-2-one compounds useful in treating circulatory disorders, particularly cardiovascular disorders, is defined by Formula I:
  • m is a number selected from one to four, inclusive; wherein R 1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, thienylalkyl,
  • phenylalkyl polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, cycloalkylcarbonyl,
  • cycloalkylalkylcarbonyl aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl,
  • alkylthiocarbonyl alkylthiocarbonyl, alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl,
  • alkylthiocarbonyl alkylsulfinyl, alkylsulfonyl
  • arylsulfonyl heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
  • X is oxygen atom or sulfur atom
  • each of R 12 and R 13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 12 and R 13 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R 12 and R 13 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; wherein each of R 0 and R 2 through R 11 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo
  • cycloalkylhaloalkyl cycloalkylcarbonyl, alkoxy
  • polycycloalkylalkyl phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
  • aralkylhaloalkyl aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl,
  • alkoxycarbonyl alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,
  • alkylcarbonyloxyalkyl alkoxycarbonylalkyl
  • mercaptocarbonyl mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
  • alkylthiothiocarbonyl alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
  • alkylsulfonyl aralkylsulfinyl, aralkylsulfonyl,
  • arylsulfinyl arylsulfonyl
  • phthalimido phthalimidoalkyl
  • heteroaryl heteroarylalkyl
  • phthalimidoalkyl heteroaryl
  • heteroarylalkyl cycloheteroalkyl
  • each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 0 and R 2 through R 11 may be further independently selected from amino and amido radicals of the formula
  • X is oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R 14 through R 26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
  • cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 14 and R 15 taken together, R 16 and R 17 taken together, R 18 and R 19 taken together, R 21 and R 22 taken together and R 23 and R 24 taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 14 and R 15 taken together, R 16 and R 17 taken together, R 21 and R 22 taken together and R 23 and R 24 taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic
  • heterocyclic group may further contain one or more
  • each of R 0 and R 3 through R 11 may be further independently selected from hydroxy and acidic moieties of the formula
  • n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;
  • Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R 0 through R 26 , Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio,
  • R 27 through R 31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR 32 and
  • D is selected from oxygen atom and sulfur atom and R 32 is selected from hydrido, alkyl, cycloalkyl,
  • R 27 , R 28 , R 29 , R 30 , R 31 , R 33 and R 34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,
  • X is oxygen atom or sulfur atom
  • each of R 28 and R 29 taken together and each of R 33 and R 34 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • Compounds of Formula I would be useful in treating a variety of circulatory disorders, including cardiovascular disorders, such as hypertension, congestive heart failure and arteriosclerosis, and to treat other disorders such as glaucoma. These compounds would also be useful as adjunctive therapies.
  • cardiovascular disorders such as hypertension, congestive heart failure and arteriosclerosis
  • compounds of Formula I may be used in combination with other drugs, such as a diuretic, to treat hypertension.
  • compounds of Formula I could be used in conjunction with certain surgical procedures. For example, these compounds could be used to prevent post-angioplasty re-stenosis.
  • Compounds of Formula I are therapeutically effective in treatment of cardiovascular disorders by acting as antagonists to, or blockers of, the angiotensin II (AII) receptor.
  • AII angiotensin II
  • acidic group selected to contain at least one acidic hydrogen atom is intended to embrace chemical groups which, when attached to any of the R 0 and R 3 through R 11 positions of Formula I, confers acidic character to the compound of Formula I.
  • acidic character means proton-donor
  • Formula I to be a proton donor in the presence of a proton- receiving substance such as water.
  • the acidic group should be selected to have proton-donor capability such that the product compound of Formula I has a pK a in a range from about one to about twelve. More typically, the Formula I compound would have a pK a in a range from about two to about seven.
  • containing at least one acidic hydrogen atom is carboxyl group (-COOH).
  • n is zero and A is -COOH, in the -Y n A moiety, such carboxyl group would be attached directly to one of the R 0 and R 3 through R 11 positions.
  • the Formula I compound may have one -Y n A moiety attached at one of the R 3 through R 11 positions, or may have a plurality of such -Y n A moieties attached at more than one of the R 0 and R 3 through R 11 positions, up to a maximum of ten such -Y n A moieties.
  • carboxyl group selectable to contain at least one acidic hydrogen atom.
  • Such other acidic groups may be
  • bioisosteres of carboxylic acid or referred to as “acidic bioisosteres”. Specific examples of such acidic bioisosteres are described
  • Compounds of Formula I having the -Y n A moiety attached at one of positions R 0 , R 5 , R 6 , R 8 and R 9 would be expected to have preferred properties, while attachment at R 5 or R 9 would be more preferred.
  • Compounds of Formula I having the -Y n A moiety attached at one of positions R 5 , R 6 , R 8 and R 9 would be expected to have preferred properties, while attachment at R 5 or R 9 would be more preferred.
  • Compounds of Formula I may have one or more acidic protons and, therefore, may have one or more pK a values.
  • pK a values of the Formula I compound as conferred by the -Y n A moiety be in a range from about two to about seven.
  • the -Y n A moiety may be attached to one of the R 3 through R 11 positions through any portion of the -Y n A moiety which results in a Formula I compound being relatively stable and also having a labile or acidic proton to meet the foregoing pK a criteria.
  • the tetrazole is attached at the ring carbon tetrazole atom.
  • a preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl,
  • cycloalkylalkylcarbonyl aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
  • alkylthiocarbonyl arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
  • X is oxygen atom or sulfur atom
  • each of R 12 and R 13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R 0 and R 2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
  • cycloalkylcarbonyl alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
  • alkylcarbonyloxyalkyl alkoxycarbonylalkyl
  • alkylthiothiocarbonyl alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
  • alkylsulfinyl alkylsulfonyl, aralkylsulfinyl
  • aralkylsulfonyl arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,
  • heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 0 and R 2 through R 11 may be further independently selected from amino and amido radicals of the formula
  • X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R 14 through R 26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
  • each of R 3 through R 11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
  • cycloalkynyl cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,
  • alkylthiocarbonyloxy alkylthiocarbonylthio
  • X is oxygen atom or sulfur atom
  • each of R 0 and R 3 through R 11 may be further independently selected from acidic moieties of the formula -Y n A wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,
  • cycloalkylalkyl alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R 0 through R 26 , y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl. alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
  • R 27 through R 31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR 32 and
  • D is selected from oxygen atom and sulfur atom
  • R 32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 27 ,
  • R 28 , R 29 , R 30 , R 31 , R 33 and R 34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,
  • a more preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from alkyl, hydroxyalkyl, haloalkyl,
  • each of R 12 and R 13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R 0 and R 2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
  • cycloalkylcarbonyl alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
  • alkoxycarbonylalkyl aralkoxycarbonylalkyl
  • aralkylcarbonyloxyalkyl alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,
  • alkylsulfonyl aralkylsulfinyl, aralkylsulfonyl,
  • arylsulfinyl arylsulfonyl
  • phthalimido phthalimidoalkyl
  • heteroaryl heteroarylalkyl
  • phthalimidoalkyl heteroaryl
  • heteroarylalkyl cycloheteroalkyl
  • each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 0 and R 2 may be further independently selected from amino and amido radicals of the formula
  • X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R 14 through R 26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
  • each of R 3 through R 11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
  • haloalkyl cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
  • alkoxycarbonyl alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
  • each of R 0 and R 3 through R 11 may be further independently selected from acidic moieties of the formula
  • n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
  • each W is independently selected from oxygen atom, sulfur atom and NR 39 ; wherein each of R 35 , R 36 , R 37 , R 38 and R 39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,
  • R 35 , R 36 , R 37 and R 39 may be further independently selected from amino radical of the formula
  • each of R 40 and R 41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 40 and R 41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
  • R 40 and R 41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R 36 and R 37 may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3 through R 11 or may be attached at any two adjacent positions selected
  • X is selected from oxygen atom and sulfur atom; wherein R 27 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR 32 and
  • D is selected from oxygen atom and sulfur atom; wherein R 32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 27 , R 28 , R 29 , R 30 , R 31 , R 33 and R 34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,
  • alkoxyalkyl alkanoyl, alkoxycarbonyl, carboxyl,
  • An even more preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl,
  • each of R 12 and R 13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R 0 and R 2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
  • cycloalkylcarbonyl alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
  • alkylcarbonyloxyalkyl alkoxycarbonylalkyl
  • mercaptocarbonyl mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
  • each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 2 through R 11 may be further independently selected from amino and amido radicals of the formula
  • X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R 14 through R 26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
  • each of R 3 through R 11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
  • haloalkyl cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
  • R 0 and R 3 through R 11 may be further independently selected from acidic moieties of the formula
  • n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
  • each W is independently selected from oxygen atom, sulfur atom and NR 39 ; wherein each of R 35 , R 38 and R 39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,
  • R 35 and R 39 may be further independently selected from amino radical of the formula
  • each of R 40 and R 41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 40 and R 41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially
  • R 40 and R 41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of
  • carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which
  • heterocyclic ring may be attached at a single position selected from R 3 through R 11 or may be attached at any two adjacent positions selected from R 3 through R 11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;
  • Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R 0 through R 26 , R 35 and R 38 through R 41 , Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy
  • Formula I consists of those compounds wherein m is one; wherein R 1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
  • each of R 12 and R 13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R 0 and R 2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
  • cycloalkylcarbonyl alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
  • alkoxyalkyl alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,
  • aralkylcarbonyloxyalkyl mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
  • cycloalkylalkylthio phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
  • each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 0 and R 2 through R 11 may be further independently selected from amino and amido radicals of the formula
  • X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R 14 through R 26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
  • each of R 3 through R 11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
  • haloalkyl cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl,
  • each of R 0 and R 3 through R 11 may be further independently selected from acidic moieties of the formula -Y n A wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
  • each W is independently selected from oxygen atom, sulfur atom and NR 39 ; wherein each of R 35 , R 38 and R 39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R 35 and R 39 may be further independently selected from amino radical of the formula wherein each of R 40 and R 41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which
  • heterocyclic ring unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3 through R 11 or may be attached at any two adjacent positions selected from R 3 through R 11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;
  • Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R 0 through R 26 , R 35 and R 38 through R 41 , Y and A and independently may be substituted at any
  • alkylsulfonyl haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • An even more highly preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkylalkylcarbonyl,
  • R 0 and R 2 is independently selected from hydrido, alkyl, aminoalkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
  • cycloalkylhaloalkyl cycloalkylcarbonyl, alkoxy
  • polycycloalkylalkyl phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
  • aralkylhaloalkyl benzoyl, phenoxy, phenoxyalkyl,
  • alkoxyalkyl acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,
  • alkylcarbonyl alkylcarbonyloxy, mercaptoalkyl
  • aralkylcarbonyloxyalkyl phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio,
  • X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R 14 through R 26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
  • each of R 3 through R 11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
  • each of R 0 and R 3 through R 11 may be further independently selected from acidic moieties consisting of CO 2 H, CO 2 CH 3 , SH, CH 2 SH, C 2 H 4 SH, PO 3 H 2 , NHSO 2 CF 3 ,
  • CONHOC 2 H 5 CONHCF 3 , OH, CH 2 OH, C 2 H 4 OH, OPO 3 H 2 , OSO 3 H ,
  • each of R 42 , R 43 and R 44 is independently selected from H, Cl, CN, NO 2 , CF 3 , C 2 F 5 , C 3 F 7 , CHF 2 , CH 2 F, CO 2 CH 3 , CO 2 C 2 H 5 , SO 2 CH 3 , SO 2 CF 3 and SO 2 C 6 F 5 ;
  • Z is selected from O, S, NR 45 and CH 2 - wherein R 45 is selected from hydrido, CH 3 and CH 2 C 6 H 5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R 3 through R 11 so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from
  • esters, amides and salts of said acidic moieties or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • a class of compounds of particular interest consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
  • cyclopropylmethyl cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
  • cyclopentenylethyl cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
  • adamantylmethyl adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
  • R 0 is selected from hydrido
  • cyclohexylethyl cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, difluoromethyl, CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,
  • each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propyltkio,
  • each of R 3 through R 11 is hydrido with the proviso that at least one of R 5 , R 6 , R 8 and R 9 is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,
  • each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • a class of compounds of more particular interest consists of those compounds of Formula I wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • R 0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
  • cyclohexylethyl cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio, butylthio, CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,
  • each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
  • each of R 3 through R 11 is hydrido with the proviso that at least one of R 5 , R 6 , R 8 and R 9 is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,
  • each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • a class of compounds of even more particular interest consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from methyl, ethyl,
  • tertbutyl 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl, cyclopentenylethyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-o
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,
  • cyclobutyl cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
  • R 3 , R 4 , R 6 , R 7 , R 8 , R 10 and R 11 is hydrido; wherein one of R 5 and R 9 is hydrido and the other of R 5 and R 9 is an acidic group selected from COOH, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,
  • each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • a class of compounds of even more particular interest consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 0 is selected from hydrido, methyl, fluoro, chloro,
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl.
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
  • R 8 , R 10 and R 11 is hydrido; with the proviso that at least one of R 5 and R 9 must be selected from COOH, SH, PO 3 H 2 SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,
  • each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • a class of compounds of even greater particular interest consists of those compounds of Formula I wherein m is one; wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl, cyclopentenylethyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 0 is selected from hydrido, methyl, fluoro, chloro,
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, eyelohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • adamantylethyl phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 0 is selected from hydrido, methyl, fluoro, chloro,
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • cyclopropylethyl cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • R 5 is an acidic group selected from CO 2 H and
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
  • cyclopropylmethyl cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
  • cyclopentenylethyl cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
  • adamantylmethyl adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
  • R 0 is hydrido; wherein R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
  • cyclobutyl cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
  • cyclopentenylpropyl cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
  • R 5 is an acidic group selected from CO 2 H and or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
  • a family of specific compounds of particular interest within Formula II consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
  • R 0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R 5 is an acidic group selected from CO 2 H and
  • a family of specific compounds of particular interest within Formula III consists of compounds and
  • a family of specific compounds of particular interest within Formula III consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
  • R 0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R 5 is an acidic group selected from CO 2 H and
  • a family of specific compounds of particular interest within Formula IV consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • a family of compounds of more particular interest within Formula IV consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1 -oxopropyl, 1-oxobutyl, 1-oxopentyl and
  • R 0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R 5 is an acidic group selected from CO 2 H and
  • a family of specific compounds of particular interest within Formula V consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • a family of compounds of more particular interest within Formula V consists of compounds and pharmaceutically-acceptable salts thereof as follows: 1-propyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2- phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and
  • R 0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
  • R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R 5 is an acidic group selected from CO 2 H and
  • a family of specific compounds of particular interest within Formula VI consists of compounds and pharmaceutically-acceptable salts thereof as follows:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of the formula <CHEM> wherein A is selected from <CHEM> wherein m is one; wherein R<1> is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R<0> is hydrido; wherein R<2> is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R<3>, R<4>, R<6>, R<7>, R<8>, R<9>, R<1><0> and R<1><1> is hydrido and R<5> must be selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, <CHEM> wherein each of R<4><2> and R<4><3> is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-aceptable salt thereof.

Description

N-ARYLHETEROARYIALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS
Related Application
This a continuation-in-part of U.S. Application Ser. No. 07/681,011 filed 5 April 1991.
Field of the Invention
Non-peptidic N-arylheteroarylalkyl imidazol-2-one compounds are described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Of particular interest are angiotensin II antagonist compounds provided by an imidazol-2-one having a arylheteroarylmethyl moiety attached to a nitrogen atom of the imidazol-2-one.
Background of the Invention
The renin-angiotensin system is one of the hormonal mechanisms involved in regulation of
pressure/volume homeostasis and in expression of
hypertension. Activation of the renin-angiotensin cascade begins with renin secretion from the juxtaglomerular apparatus of the kidney and culminates in the formation of angiotensin II, the primary active species of this system. This octapeptide, angiotensin II, is a potent
vasoconstrictor agent and also produces other physiological effects such as promoting aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, increasing vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems.
Previous studies have shown that antagonizing angiotensin II at its receptors is a viable approach to inhibit the renin-angiotensin system, given the pivotal role of this octapeptide which mediates the actions of the renin-angiotensin system through interaction with various tissue receptors. There are several known angiotensin II antagonists, most of which are peptidic in nature. Such peptidic compounds are of limited use due to their lack of oral bioavailability or their short duration of action. Also, commercially-available peptidic angiotensin II antagonists (e.g., Saralasin) have a significant residual agonist activity which further limit their therapeutic application.
Non-peptidic compounds with angiotensin II antagonist properties are known. For example, the sodium salt of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5- acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [P. C. Wong et al, J. Pharmacol. Exp. Ther., 241(1), 1-7 (1988)]. Also, the sodium salt of 2-butyl-4-chloro-1-(2-nitrobenzyl)imidazole-5-acetic acid has specific
competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [A. T. Chiu et al, European J, Pharmacol., 157, 13-21 (1988)]. A family of 1-benzylimidazole-5-acetate derivatives has been shown to have competitive angiotensin II antagonist properties [A. T. Chiu et al, J. Pharmacol. Exp. Ther., 250 (3) , 867-874 (1989)]. U.S. Patent No.
4,816,463 to Blankey et al describes a family of 4,5,6,7-tetrahydro-1H-imidazo(4,5-c)-tetrahydro-pyridine
derivatives useful as antihypertensives, some of which are reported to antagonize the binding of labelled angiotensin II to rat adrenal receptor preparation and thus cause a significant decrease in mean arterial blood pressure in conscious hypertensive rats. EP No. 253,310, published 20 January 1988, describes a series of aralkyl imidazole compounds, including in particular a family of
biphenylmethyl substituted imidazoles, as antagonists to the angiotensin II receptor. EP No. 323,841 published 12 July 1989 describes four classes of angiotensin II antagonists, namely, biphenylmethylpyrroles,
biphenylmethylpyrazoles, biphenylmethyl-1,2,3-triazoles and biphenylmethyl 4-substituted-4H-1,2,4-triazoles, including the compound 3,5-dibutyl-4-[(2'-carboxybiphenyl-4- yl)methyl]-4H-1,2,4-triazole. U.S. Patent No. 4,880,804 to Carini et al describes a family of
biphenylmethylbenzimidazole compounds as angiotensin II receptor blockers for use in treatment of hypertension and congestive heart failure.
There are several families of known compounds having one or two oxo substituents on a triazole ring. For example, East German Patent No. 160,447 published 3 August 1983 describes a family of 1,2,4-triazolin-5-one compounds, specifically 2,4-dihydro-4,5-bis(phenylmethyl)-3H-1,2,4-triazol-3-one, for use as herbicides. Belgian Patent No. 806,146 published 16 October 1972 describes a family of triazolinone compounds, including the compound (3-(4-m-chlorophenyl-1-piperazinyl)-propyl)-3,4-diethyl-1,2,4-triazolin-5-one, having tranquilizer, hypotensive and analgesic activities. Belgian Patent No. 631,842 published 28 February 1963 describes a family of 1,2, 4-triazolones having hypnotic, tranquilizer, narcotic, sedative and analgetic activities, which includes a class of 4-N-aralkyl-1,2,4-triazol-5-one compounds. EP #7,180 published 15 June 1978 describes a family of 1,2-disubstituted-4-alkyl-1,2,4-triazolidine-3,5-dione compounds having a wide variety of activities, such as antiulcer, bronchodilator, antifertility and cardiovascular-related activities which include antihypertensive, antiarrhythmic, platelet
aggregation inhibition and smooth muscle activities.
EP #283,310 published 18 March 1987 describes a family of N1-diarylmethyl-N2-aminoalkyl-diaza-heterocyclic
derivatives for treating cerebral vascular and ischemic diseases and for protecting against anoxia. DESCRIPTION OF THE INVENTION
A class of N-substituted arylheteroarylalkyl imidazol-2-one compounds useful in treating circulatory disorders, particularly cardiovascular disorders, is defined by Formula I:
wherein A is selected from
wherein m is a number selected from one to four, inclusive; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, thienylalkyl,
phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, cycloalkylcarbonyl,
cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl,
alkylthiocarbonyl, alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl,
alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,
aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R12 and R13 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R12 and R13 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; wherein each of R0 and R2 through R11 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, alkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R14 and R15 taken together, R16 and R17 taken together, R18 and R19 taken together, R21 and R22 taken together and R23 and R24 taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R14 and R15 taken together, R16 and R17 taken together, R21 and R22 taken together and R23 and R24 taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic
heterocyclic group may further contain one or more
additional nitrogen atoms; and wherein each of R0 and R3 through R11 may be further independently selected from hydroxy and acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;
wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR32 and
wherein D is selected from oxygen atom and sulfur atom and R32 is selected from hydrido, alkyl, cycloalkyl,
cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl, and wherein each of R27, R28, R29, R30, R31, R33 and R34 is further
independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R35, R36, R37, R38, R39 and R40 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R28 and R29 taken together and each of R30 and R31 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein each of R28 and R29 taken together and each of R33 and R34 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
Compounds of Formula I would be useful in treating a variety of circulatory disorders, including cardiovascular disorders, such as hypertension, congestive heart failure and arteriosclerosis, and to treat other disorders such as glaucoma. These compounds would also be useful as adjunctive therapies. For example, compounds of Formula I may be used in combination with other drugs, such as a diuretic, to treat hypertension. Also, compounds of Formula I could be used in conjunction with certain surgical procedures. For example, these compounds could be used to prevent post-angioplasty re-stenosis. Compounds of Formula I are therapeutically effective in treatment of cardiovascular disorders by acting as antagonists to, or blockers of, the angiotensin II (AII) receptor. Compounds of Formula I would be therapeutically effective in
treatment of the above-mentioned circulatory and cardiovascular disorders or would be precursors to, or prodrugs of, therapeutically-effective compounds.
The phrase "acidic group selected to contain at least one acidic hydrogen atom", as used to define the -YnA moiety, is intended to embrace chemical groups which, when attached to any of the R0 and R3 through R11 positions of Formula I, confers acidic character to the compound of Formula I. "Acidic character" means proton-donor
capability, that is, the capacity of the compound of
Formula I to be a proton donor in the presence of a proton- receiving substance such as water. Typically, the acidic group should be selected to have proton-donor capability such that the product compound of Formula I has a pKa in a range from about one to about twelve. More typically, the Formula I compound would have a pKa in a range from about two to about seven. An example of an acidic group
containing at least one acidic hydrogen atom is carboxyl group (-COOH). Where n is zero and A is -COOH, in the -YnA moiety, such carboxyl group would be attached directly to one of the R0 and R3 through R11 positions. The Formula I compound may have one -YnA moiety attached at one of the R3 through R11 positions, or may have a plurality of such -YnA moieties attached at more than one of the R0 and R3 through R11 positions, up to a maximum of ten such -YnA moieties.
There are many examples of acidic groups other than
carboxyl group, selectable to contain at least one acidic hydrogen atom. Such other acidic groups may be
collectively referred to as "bioisosteres of carboxylic acid" or referred to as "acidic bioisosteres". Specific examples of such acidic bioisosteres are described
hereinafter. Compounds of Formula I having the -YnA moiety attached at one of positions R0, R5, R6, R8 and R9 would be expected to have preferred properties, while attachment at R5 or R9 would be more preferred. Compounds of Formula I having the -YnA moiety attached at one of positions R5, R6, R8 and R9 would be expected to have preferred properties, while attachment at R5 or R9 would be more preferred. Compounds of Formula I may have one or more acidic protons and, therefore, may have one or more pKa values. It is preferred, however, that at least one of these pKa values of the Formula I compound as conferred by the -YnA moiety be in a range from about two to about seven. The -YnA moiety may be attached to one of the R3 through R11 positions through any portion of the -YnA moiety which results in a Formula I compound being relatively stable and also having a labile or acidic proton to meet the foregoing pKa criteria. For example, where the -YnA acid moiety is tetrazole, the tetrazole is attached at the ring carbon tetrazole atom.
A preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
alkylthiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto,
alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,
aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,
cycloheteroalkyl, cycloheteroalkylalkyl and
cycloheteroalkylcarbonylalkyl wherein each of said
heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,
cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,
alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, arylthio, arylthiocarbonyl,
arylcarbonylthio, arylthiocarbonyloxy,
arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula -YnA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,
cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl. alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR32 and
wherein D is selected from oxygen atom and sulfur atom, and R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27,
R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,
alkoxycarbonyl, carboxyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A more preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl ,
alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R36, R37, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,
cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R35, R36, R37 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R36 and R37 may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R0 through R26 and R35 through R41, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl,
hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein R27 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR32 and
wherein D is selected from oxygen atom and sulfur atom; wherein R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,
alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. An even more preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl,
cycloalkenyl, alkynyl, mercaptocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,
cycloalkylalkyl, aryl and aralkyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of
carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which
heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A highly preferred class of compounds within
Formula I consists of those compounds wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,
carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
)
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula -YnA wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially
unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A and independently may be substituted at any
substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,
alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. An even more highly preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkenyl and alkynyl; where each of R0 and R2 is independently selected from hydrido, alkyl, aminoalkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,
alkylcarbonyl, alkylcarbonyloxy, mercaptoalkyl,
mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio,
cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula
;
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R 11 may be further independently selected from acidic moieties consisting of CO2H, CO2CH3, SH, CH2SH, C2H4SH, PO 3H2, NHSO2CF3 ,
NHSO 2C6F5, SO 3H, CONHNH2, CONHNHSO2 CF3 , CONHOCH 3 ,
CONHOC 2H5, CONHCF 3 , OH, CH2OH, C2H4OH, OPO 3H2, OSO 3H ,
wherein each of R42, R43 and R44 is independently selected from H, Cl, CN, NO2, CF3, C2F5, C3F7, CHF2, CH2F, CO2CH3, CO2C2H5, SO2CH3, SO2CF3 and SO2C6F5; wherein Z is selected from O, S, NR45 and CH2- wherein R45 is selected from hydrido, CH3 and CH2C6H5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R3 through R11 so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from
and the esters, amides and salts of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A class of compounds of particular interest consists of those compounds of Formula I wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl,
1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido,
C4H9(n), CH3CH2CH=CH, C3H7(n), SC3H7,
C2H5, C5H11(n), C6H13(n), SC4H9, ,
CH3CH=CH, CH3CH2CH2CH=CH-, amino, aminomethyl, aminoethyl, aminopropyl, CH2OH, CH2OCOCH3, CH2CI, CH2OCH3, CH2OCH(CH3)2, CHO,
CH2CO2H, CH (CH3) CO2H, NO2, Cl,
,
- -CO2CH3, -CONH2, -CONHCH3, CON (CH3) 2,
-CH2-NHCO2C2H5, -CH2NHCO2CH3, -CH2NHCO 2C3H7,
-CH2NHCO2CH2(CH3) 2, -CH2NHCO 2C4H9, CH2NHCO2-adamantyl,
-CH2NHCO2- (1-napthyl) , -CH2NHCONHCH3, -CH2NHCONHC 2H5,
-CH2NHCONHC 3H7, -CH2NHCONHC4H9, -CH2NHCONHCH (CH3) 2,
-CH 2NHCONH ( 1-napthyl) , -CH2NHCONH (1-adamantyl) , , -CH2CH2CH2CO2H,
-CH2CH2F, -CH2OCONHCH 3, -CH2OCSNHCH 3, -CH2NHCSOC 3H7,
-CH2CH2CH2F, -CH2ONO2, -CH2SH,
Cl, NO2, CF3, CH2OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, cyclohexyl,
cyclohexylmethyl, carboxyl, formyl, 1-oxoethyl,
1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, 1,1-dimethoxypropyl, 1, -dimethoxypentyl, hydroxyalkyl, halo, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,
1,1-difluoro-2-phenylethyl, monofluoromethyl,
1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,
1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,
1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, difluoromethyl, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propyltkio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A class of compounds of more particular interest consists of those compounds of Formula I wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1- oxopentyl 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio, butylthio, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A class of compounds of even more particular interest consists of those compounds of Formula I wherein m is one; wherein R1 is selected from methyl, ethyl,
n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,
tertbutyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl,
1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,
neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R5 and R9 is an acidic group selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A class of compounds of even more particular interest consists of those compounds of Formula I wherein m is one; wherein R1 is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, eyelobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl. adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7,
R8, R10 and R11 is hydrido; with the proviso that at least one of R5 and R9 must be selected from COOH, SH, PO3H2 SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A class of compounds of even greater particular interest consists of those compounds of Formula I wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, eyelohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R5 and R9 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
Within Formula I there is a sub-class of
compounds of high interest as represented by Formula II:
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl. fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
Within Formula II there is a more preferred subclass of compounds of high interest wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A family of specific compounds of particular interest within Formula II consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-methyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol- 5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl) phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-methyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl) phenyl] -2-pyridinyl] methyl ] -2H-imidazol-2-one;
1-isopropyl-4-pentyl-1, 3-dihydro-3- [ [5- [2- (1H-tetrazol-5 - yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-pentyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1,5-dimethyl-4-propyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol- 5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-butyl-5-methyl-1, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-pentyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-butyl-4-pentyl-5-methyl-1, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-secbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1,4-dipentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-methyl-4-propyl-5-chloro-1, 3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-phenyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[5-[2 - (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-ethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol- 5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-5-chloro-1, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-butyl-5-chloro-1, 3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-5-chloro-1, 3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-pentyl-5-chloro-1, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1,4-dipentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one. A family of specific compounds of more
particular interest within Formula II consists of compounds and pharmaceutically-acceptable salts thereof as follows: 1-propyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazo1-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-methyl-1, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one.
Within Formula I there is second sub-class of compounds of high interest as represented by Formula III:
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1 -oxopropyl, 1-oxobutyl, 1-oxopentyl and
2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A family of specific compounds of particular interest within Formula III consists of compounds and
pharmaceutically-acceptable salts thereof as follows:
1-methyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-isopropyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol- 5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl) phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one; 1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-methyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-pentyl-1, 3-dihydro-3- [ [6- [2- (1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,5-dimethyl-4-propyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-butyl-4-propyl-5-methyl-1, 3-dihydro-3- [ [ 6- [2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one; 1, 5-dimethyl-4-butyl-1, 3-dihydro-3- [ [ 6- [2- (1H-tetrazol-5 - yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol- 5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-methyl-1, 3-dihydro-3- [ [ 6- [2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-propyl-5-chloro-l , 3-dihydro-3- [ [ 6- [2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-ethyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol- 5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one;
1-secbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl) phenyl ] -3-pyridinyl] methyl] -2H-imidazol-2-one;
1-isopropyl-4-pentyl-5-chloro-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl) phenyl ] -3-pyridinyl] methyl ] -2H-imidazol-2-one;
1, 4-dipentyl-5-chloro-1,3-dihydro-3- [ [ 6- [2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-imidazol-2-one; 1-cyclohexyl-4-pentyl-5-chloro-1, 3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one. or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A family of specific compounds of particular interest within Formula III consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-o_ιe;
1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl) phenyl] -3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-1 , 3-dihydro-3- [ [ 6- [2- (1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-butyl-5-chloro-1, 3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
11-cyclohexylmethyl-4-butyl-5-chloro-1, 3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol- 2-one. Within Formula I there is third sub-class of compounds of high interest as represented by Formula IV:
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1 -oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within Formula IV consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-methyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-propyl-1, 3-dihydro-3- [ [4- [3- (1H-tetrazol-5 - yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-propyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-methyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyriciinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexyl-4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5 - yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-pentyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,5-dimethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dipropyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-propyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl] phenyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl) -2-pyridinyl]phenyl] methyl ] -2H-imidazol-2- one;
1-cyclohexyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-methyl-1,3-dιhydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl] phenyl]methyl]-2H-imidazol-2-one; 1-ethyl-4-pentyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl) -2-pyridinyl]phenyl] methyl] -2H-imidazol-2- one;
1-ethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dipropyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-propyl-5-chloro-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isobutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-propyl-4-pentyl-5-chloro-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; and
1- (2-phenylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
A family of compounds of more particular interest within Formula IV consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and 1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one. Within Formula I there is fourth a sub-class of compounds of high interest as represented by Formula V:
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1 -oxopropyl, 1-oxobutyl, 1-oxopentyl and
2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within Formula V consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-methyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-phenylethyl)-4-propyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-methyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-methyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-phenylethyl)-4-pentyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imi-dazol-2- one;
1-methyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-ethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dipropyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-{4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-butyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-secbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,5-dimethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-butyl-4-pentyl-5-methyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-methyl-4-propyl-5-chloro-1,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-ethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dipropyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-butyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-secbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-phenyl-4-propyl-5-chloro-1,3-dihydro-3- [ [4- [4- <1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-14-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-pentyl-5-chloro-1,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
A family of compounds of more particular interest within Formula V consists of compounds and pharmaceutically-acceptable salts thereof as follows: 1-propyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
Within Formula I there is fifth sub-class of compounds of high interest as represented by Formula VI:
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2- phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and
2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A family of specific compounds of particular interest within Formula VI consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-methyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-propyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol- 5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isόbutyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-methyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-tertbutyl-4-pentyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5 - yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)- 4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,5-methyl-4-propyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isobutyl-4-propyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]—2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,5-dimethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopropyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyi]-2H-imidazol-2-one; 1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-pentyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-butyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-secbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-phenyl-4-pentyl-5-methyl-1,3-dihydro-3- [ [ 4- [3- ( 1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methzl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-butyl-5-chloro-1,3-dihydro-3- [ [ 4- [3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-ethyl-4-pentyl-5-chloro-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-((H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-{3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-butyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-secbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl) -4-pyridinyl]phenyl] methyl ] -2H-imidazol-2-one; 1 -phenylmethyl-4-pentyl-5-chloro-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
A family of compounds of more particular interest within Formula VI consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
Within Formula I there is sixth sub-class of compounds of high interest as represented by Formula VII:
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2- phenethyl, 1 -oxopropyl, 1-oxobutyl, 1-oxopentyl and
2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl;
wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl and cyclohexylethyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
A family of specific compounds of particular interest within Formula VII consists of compounds and pharmaceutically-acceptable salts thereof as follows:
1-methyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-ethyl-4-propyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) -3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-propyl-4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) -3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopropyl-4-pentyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5 - yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)- 3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,5-dimethyl-4-propyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopropyl-4-propyl-5-methyl-1,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl] methyl] -2H-imidazol-2- one;
1-butyl-4-propyl-5-methyl-1,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl ] -2H-imidazol-2- one;
1-secbutyl-4-propyl-5-methyl-1,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one;
1-isobutyl-4-propyl-5-methyl-1,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-phenylethyl)-4-propyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-phenyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1,5-dimethyl-4-pentyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-butyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-pentyl-5-methyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-pentyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-butyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-secbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isobutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-tertbutyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-pentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-propyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-ethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-methyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-ethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopropyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-butyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-secbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dipentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexyl-4-pentyl-5-chloro-1,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-pentyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl) -3-pyridinyl]phenyl] methyl] -2H-imidazol- 2-one . A family of compounds of more particular interest within Formula VII consists of compounds and pharmaceutically-acceptable salts as follows:
1-propyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[2(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2(1H-tetrazol- 5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4- [2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4- [2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1- (2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
The term "hydrido" denotes a single hydrogen atom (H). This hydrido group may be attached, for example, to an oxygen atom to form a hydroxyl group; or, as another example, one hydrido group may be attached to a carbon atom to form a group; or, as another example, two hydrido groups may be attached to a carbon atom to form a -CH2- group. Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about five carbon atoms. The term
"cycloalkyl" embraces cyclic radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with one or more halo groups, preferably selected from bromo, chloro and fluoro. Specifically embraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl and
polyhaloalkyl groups. A monohaloalkyl group, for example, may have either a bromo, a chloro, or a fluoro atom within the group. Dihaloalkyl and polyhaloalkyl groups may be substituted with two or more of the same halo groups, or may have a combination of different halo groups. A
dihaloalkyl group, for example, may have two fluoro atoms, such as difluoromethyl and difluorobutyl groups, or two chloro atoms, such as a dichloromethyl group, or one fluoro atom and one chloro atom, such as a fluoro-chloromethyl group. Examples of a polyhaloalkyl are trifluoromethyl, 1,1-1ifluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl and 2,2,3,3-tetrafluoropropyl groups. The term "difluoroalkyl" embraces alkyl groups having two fluoro atoms substituted on any one or two of the alkyl group carbon atoms. The terms "alkylol" and "hydroxyalkyl" embrace linear or branched alkyl groups having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl groups. The term "alkenyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon double bond, which carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably two to about ten carbon atoms, and containing at least one carbon-carbon triple bond. The term
"cycloalkenyl" embraces cyclic radicals having three to about ten ring carbon atoms including one or more double bonds involving adjacent ring carbons. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy group. The term
"alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy groups attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl groups. The
"alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl groups. The term "alkylthio" embraces radicals containing a linear or branched alkyl group, of one to about ten carbon atoms attached to a divalent sulfur atom, such as a methythio group. Preferred aryl groups are those consisting of one, two, or three benzene rings. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl and biphenyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, phenylbutyl and diphenylethyl. The terms "benzyl" and "phenylmethyl" are interchangeable. The terms
"aryloxy" and "arylthio" denote radical respectively, aryl groups having an oxygen or sulfur atom through which the radical is attached to a nucleus, examples of which are phenoxy and phenylthio. The terms "sulfinyl" and "sulfonyl", whether used alone or linked to other terms, denotes respectively divalent radicals SO and SO2. The term "aralkoxy", alone or within another term, embraces an aryl group attached to an alkoxy group to form, for example, benzyloxy. The term "acyl" whether used alone, or within a term such as acyloxy, denotes a radical provided by the residue after removal of hydroxyl from an organic acid, examples of such radical being acetyl and benzoyl. "Lower alkanoyl" is an example of a more prefered sub-class of acyl. The term "amido" denotes a radical consisting of nitrogen atom attached to a carbonyl group, which radical may be further substituted in the manner described herein. The amido radical can be attached to the nucleus of a compound of the invention through the carbonyl moiety or through the nitrogen atom of the amido radical. The term "alkenylalkyl" denotes a radical having a double-bond unsaturation site between two carbons, and which radical may consist of only two carbons or may be further substituted with alkyl groups which may optionally contain additional double-bond unsaturation. The term "heteroaryl" embraces aromatic ring systems containing one or two hetero atoms selected from oxygen, nitrogen and sulfur in a ring system having five or six ring members, examples of which are thienyl, furanyl, pyridinyl, thiazolyl, pyrimidyl and isoxazolyl. Such heteroaryl may be attached as a
substituent through a carbon atom of the heteroaryl ring system, or may be attached through a carbon atom of a moiety substituted on a heteroaryl ring-member carbon atom, for example, through the methylene substituent of
imidazolemethyl moiety. Also, such heteroaryl may be attached through a ring nitrogen atom as long aε
aromaticity of the heteroaryl moiety is preserved after attachment. For any of the foregoing defined radicals, preferred radicals are those containing from one to about ten carbon atoms. Specific examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, methylbutyl, dimethylbutyl and neopentyl. Typical alkenyl and alkynyl groups may have one unsaturated bond, such as an allyl group, or may have a plurality of unsaturated bonds, with such plurality of bonds either adjacent, such as allene-type structures, or in conjugation, or separated by several saturated carbons. Compounds of Formula I have been found to inhibit the action of angiotensin II in mammals.
Angiotensin II is a potent vasoconstrictor and participates in the formation of aldosterone which regulates sodium and water balance in mammals. Thus, compounds of Formula I are therapeutically useful in methods for treating hypertension by administering to a hypertensive patient a
therapeutically-effective amount of a compound of
Formula I. The phrase "hypertensive patient" means, in this context, a mammalian subject suffering from or afflicted by the effects of hypertension or susceptible to a hypertensive condition if not treated to prevent or control such hypertension.
Also included in the family of compounds of Formula I are isomeric forms including diastereoisomers, regioisomers and the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicyclic, phenylacetic, mandelic, embonic (pamoic), methansulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, β-hydroxybutyric, malonic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of
Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.
General Synthetic Procedures
The compounds of the invention can be
synthesized according to the following procedures of Schemes I-XXIX, wherein the R substituents are as defined for Formula I, above, except where further noted.
Synthetic Scheme I shows the preparation of the boronic acid 1 where R5 equals N-tertbutyl-N-methylcarboxamide. In step 1, benzoic acid is treated with thionyl chloride to give the corresponding acid chloride which is subsequently reacted with N-tertbutyl-N-methylamine to give N-tertbutyl-N-methylbenzamide. In step 2, the amide is ortho-metalated and subsequently reacted with trimethyl borate. The free boronic acid 1 is produced on hydroylsis.
Synthetic Scheme II shows the preparation of the boronic acid 1 where R5 equals N-triphenylmethyl-1H-tetrazole. In step 1, 2-bromobenzonitrile (Aldrich) is reacted with tributyltin azide to give the corresponding tetrazole. In step 2, the tetrazole is reacted with triphenylmethyl chloride in the presence of triethylamine to give the protected bromophenyltetrazole. In step 3, halogen-metal interchange with n-butyllithium generates the corresponding ortho-lithiated species which is reacted with trimethyl borate. The free boronic acid 1 is produced on hydrolysis.
Synthetic Scheme III shows the preparation of N-Boc-amino ketones 2 (or aldehydes when Rº = H) from the corresponding N-Boc-amino acides 3 . In step 1, the amino acid 3 is reacted with isobutyl chloroformate in the presence of triethylamine and subsequently with N,O-dimethyIhydroxylamine to give the corresponding N-methoxy- N-methylamide 4. In step 2, the amide A is reacted with an organolithium reagent R°-Li (or lithium aluminum hydride (LAH) when R° = H) to give the desired ketone 2 (or aldehyde when R° = H).
Synthetic Scheme IV shows the preparation of imidazol-2-ones 5 from the corresponding amides 4 via Method A. In step 1, the protected amide 4 (prepared in Scheme III) is reacted with trifluoroacetic acid (TFA) to give the TFA salt 6 of the free amine. In step 2, the salt 6 is reacted with the appropriate isocyanate 7 in the presence of triethylamine to give the urea 8. In step 3, the urea & is reacted with an organolithium reagent R°-Li (or lithium aluminum hydride (LAH) when R° = H) and subsequently cyclized to the imidazole-2-one 5 on treatment with dilute acid during the work-up procedure.
Synthetic Scheme V shows the preparation of imidazol-2-ones 5 from the corresponding N-Boc-protected amino ketones 2 (or aldehydes when R° = H) via Method B. In step 1, the carbonyl compound 2 (prepared in Scheme III) is reacted with anhydrous hydrogen chloride in dioxane to give the HCl salt 9. In step 2, the salt 9 is reacted with the appropriate isocyanate 2 in chloroform to give the imidazol-2-one 5 directly.
Synthetic Scheme VI shows the preparation of imidazol-2-ones h from the corresponding N-Boc-protected amino ketones 2 (or aldehydes when R° = H) via Method C. In step 1, the carbonyl compound 2 (prepared in Scheme III) is reacted with 2,2-dimethyl-1,3-propandiol to give the cyclic ketal 10. In step 2, the ketal 10 is reacted with TFA to give the TFA salt 11 of the free amine. In step 3, the salt 11 is reacted with the appropriate isocyanate 7 in the presence of triethylamine to give the urea ketal 12. In step 4, the urea ketal 12 is reacted with 6N
hydrochloric acid at 60°C to give the desired imidazol-2-one 5 directly.
Synthetic Scheme VII shows the preparation of 2-bromomethyl-5-bromopyridine (13) and 5-bromo-2-pyridinecarboxaldehyde (14) from 2-picoline (Aldrich). In step 1, 2-picoline is reacted with bromine in the presence of a large excess of aluminum chloride at elevated temperatures to give 5-bromo-2-picoline (15). In step 2a, 15 is reacted with NBS to give the 2-pyridinylmethyl bromide 13. In step 2b, the intermediate 15 is treated with potassium permanganate to give the corresponding picolinic acid 16. In step 3b, the acid 16 is first converted to its N-methoxy-N-methylamide and subsequently reduced with LAH to provide 5-bromo-2-pyridinecarboxaldehyde (1 4).
Synthetic Scheme VIII shows the preparation of 2-bromo-5-bromomethylpyridine (17) and 2-bromo-5- pyridinecarboxaldehyde (18) from 2-amino-5-picoline (Aldrich). In step 1, 2-amino-5-picoline is reacted with bromine in the presence of hydrobromic acid and sodium nitrite at 0°C to give 2- bromo-5-picoline (19). In step 2a, 12 is reacted with NBS to give the 3-pyridinylmethyl bromide 12. In step 2b, the
intermediate 12 is treated with potassium permanganate to give the corresponding nicotinic acid 20. In step 3b, the acid 20 is first converted to its N-methoxy-N-methylamide and subsequently reduced with LAH to provide 2-bromo-5-pyridinecarboxaldehyde (18).
Synthetic Scheme IX shows the preparation of (4-bromobenzyl)imidazol-2-ones 21 from the TFA salt of the amino amide 6 (prepared in Scheme III). In step 1, the TFA salt 6 is allowed to react with the 4-bromobenzaldehyde in the presence of triethylamine and anhydrous magnesium sulfate to give the imine 22. In step 2, the imine 22 is allowed to react with sodium borohydride to give the substituted benzylamine 23. In step 3, the benzylamine 23. is allowed to react with the appropriate isocyanate 2 to give the substituted benzylurea 24. In step 4, the urea 24 is first allowed to react with an organolithium reagent R°-Li (or lithium aluminum hydride (LAH) when R° = H) and subsequently with dilute aqueous acid to give the desired 3-(4-bromobenzyl)imidazol-2-ones.
Synthetic Scheme X shows the preparation of 3-(5-bromo-2-pyridinylmethyl)imidazol-2-ones 25 from the TFA salt of the amino amide 6 (prepared in Scheme III). In step 1, the TFA salt 6 is allowed to react with the
5-bromo-2-pyridinylaldehyde 14 (prepared in Scheme VII) in the presence of triethylamine and anhydrous magnesium sulfate to give the imine 26. In step 2, the imine 26 is allowed to react with sodium borohydride to give the substituted benzylamine 27. In step 3, the benzylamine 27 is allowed to react with the appropriate isocyanate 7 to give the substituted benzylurea 28. In step 4, the urea 28 is first allowed to react with an organolithium reagent R°- Li (or lithium aluminum hydride (LAH) when R° = H) and subsequently with dilute aqueous acid to give the desired 3-(5-bromo-2-pyridinylmethyl)imidazol-2-ones 25.
Synthetic Scheme XI shows the preparation of 3-(2-bromo-5-pyridinylmethyl)imidazol-2-ones 29 from the TFA salt of the amino amide 6 (prepared in Scheme III). In step 1, the TFA salt 6 is allowed to react with 2-bromo-5- pyridinylaldehyde 18. (prepared in Scheme VIII) in the presence of triethylamine and anhydrous magnesium sulfate to give the imine 30. In step 2, the imine 30 is allowed to react with sodium borohydride to give the substituted benzylamine 31. In step 3, the benzylamine 31 is allowed to react with the appropriate isocyanate 2 to give the substituted benzylurea 32. In step 4, the urea 32 is first allowed to react with an organolithium reagent R°-Li (or lithium aluminum hydride (LAH) when R° = H) and subsequently with dilute aqueous acid to give the desired 3- (2-bromo-5- pyridinylmethyl)imidazol-2-ones 29.
Synthetic Scheme XII shows the preparation of 3-(4-bromobenzyl)imidazol-2-ones 21, 3-(5-bromo-2-pyridinylmethyl)imidazol-2-ones 25, and 3-(2-bromo-5-pyridinylmethyl)imidazol-2-ones 29 from the parent
imidazol-2-ones 9 (prepared in Scheme IV, Scheme V, or Scheme VI). The imidazol-2-one 9 is first treated with a base, such as potassium t-butoxide, and subsequently with the alkylating agent 4-bromobenzyl bromide, 13 (prepared in Scheme VII), and 17 (prepared in Scheme VIII) to give 3- (4-bromobenzyl) imidazol-2-ones 21, 3-(5-bromo-2-pyridinylmethyl)imidazol-2-ones 25, and 3-(2-bromo-5-pyridinylmethyl)imidazol-2-ones 29, respectively.
Synthetic Scheme XIII shows the preparation of 3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-ones 30 from the boronic acid 1 (prepared in Scheme I and Scheme II) and the bromoimidazol-2-one coupling reagent 25 (prepared in Scheme X and Scheme XII). The boronic acid 1 is reacted with the bromoimidazol-2-one coupling reagent 25. in the presence of a palladium zero catalyst via a Snieckus coupling [see M. J. Sharp and V. Snieckus, Tetrahedron Lett. , 5997(1985)] to give the angiotensin II antagonists 20 of this invention.
Synthetic Scheme XIV shows the preparation of 3-[[6-[2-(1H-tetrzol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-ones 31 from the boronic acid 1 (prepared in Scheme I and Scheme II) and the bromoimidazol-2-one coupling reagent 29 (prepared in Scheme XI and Scheme XII). The boronic acid 1 is reacted with the bromoimidazol-2-one coupling reagent 29 in the presence of a palladium zero catalyst via a Snieckus coupling [see M. J. Sharp and
V. Snieckus, Tetrahedron Lett., 5997 (1985)] to give the angiotensin II antagonists 21 of this invention.
Synthetic Scheme XV shows the preparation of the imidazol-2-one boronic acid coupling reagents 32 from the corresponding 3-(4-bromobenzyl)imidazol-2-ones 21 (prepared in Scheme IX and Scheme XII). Halogen-metal interchange generates the corresponding lithiated species from 21 which is reacted with trimethyl borate. The free imidazol-2-one boronic acid coupling reagents 32 are produced on acid hydrolysis.
Synthetic Scheme XVI shows the preparation of the 4-bromopyridine coupling reagent 33.
[R5 = CON (CH3)C(CH3) 3] and the 2-bromopyridine coupling reagent 21 [R5 = CON(CH3)C(CH3) 3] from nicotinic acid. In step 1, N-tertbuty-N-methylnicotinamide is prepared from nicotinoyl chloride and N-tertbutyl-N-methylamine. In step 2, ortho-metalalion with see-butyllithium gives a mixture of regioanions which are reacted with
trimethylsilyl chloride; subsequent conversion to the corresponding bromides on treatment with bromine in acetic acid and separation of the regioisomers by chromatography provides 33 and 34.
Synthetic Scheme XVII shows the preparation of the 3-bromopyridine coupling reagent 25.
[R5 = CON(CH3)C(CH3)3] from isonicotinic acid. In step 1, N-tertbutyl-N-methylisonicotinamide is prepared from isonicotinoyl chloride and N-tertbutyl-N-methylamine. In step 2, reaction with sec-butyllithium gives the
ortho-lithiated species which is reacted with
trimethylsilyl chloride and subsequently converted to the corresponding bromide 35 on treatment with bromine in acetic acid.
Synthetic Scheme XVIII shows the
preparation of the 3-bromopyridine coupling reagent 36
[R5 = CON(CH3)C(CH3)3] from picolinic acid. In step 1, N-tertbutyl-N-methylpicolinamide is prepared from
picolinoyl chloride and N-tertbutyl-N-methylamine. In step 2, reaction with sec-butyllithium gives the ortho-lithiated species which is reacted with trimethylsilyl chloride and subsequently converted to the corresponding bromide 36 on treatment with bromine in acetic acid.
Synthetic Scheme XIX shows the preparation of 3-(pyridinylbenzyl)imidazol-2-ones 37, 38, 29 and 40 from the common imidazol-2-one boronic acids 32 (Scheme XV) and the corresponding bromo coupling reagents 36 Scheme XVIII), 33 (Scheme XVI, 35 (Scheme XVII), and 34 (Scheme XVI), respectively. The boronic acids 32 are reacted with the bromo coupling reagents 36 , 33, 35 and 34 in the presence of a palladium zero catalyst via a Snieckus coupling [see M. J. Sharp and V. Snieckus, Tetrahedron Lett., 5997 (1985)] to give the angiotensin II antagonists37, 38, 39 and 40, respectively, of this invention.
Synthetic Scheme XX shows the preparation of carboxylic acid analogs 41 and 1H-tetrazole analogs 12 from analogs which have R5 = CON(CH3)C(CH3)3. In step 1, the N-tertbutyl-N-methylamide analog 43 is reacted with trifluoroacetic acid at reflux to give the N-methylamide
44. In step 2, the N-methylamide 44 is reacted with sodium nitrite in acetic anhydride/acetic acid at 0°C to give the corresponding N-methyl-N-nitrosoamide 45. In step 3, the N-methyl-N-nitrosoamide 45 is hydrolyzed in base to give the corresponding carboxylic acid angiotensin II
antagonists of this invention. In step 4, the acid analog 41 is reacted with oxalyl chloride and subsequently with anhydrous ammonia to give the primary amide 46. In step 5, the amide 46 is reacted with triphenylphosphine in carbon tetrachloride at 50°C to give the corresponding nitrile 47. In step 6, the nitrile 47 is reacted with trimethyltin azide in xylene at reflux to provide the 1H-tetrazole angiotensin II antagonists of this invention.
Synthetic Scheme XXI shows the preparation of the organozinc reagent 48 from the appropriate benzoic acid analog 49. In step 1, the analog 49 is brominated with bromine in the presence of a suitable catalyst, e.g., iron, to give the 2-bromo analog 50. In step 2, the 2-bromo analog 50 was converted to the organolithium reagent 51 by reaction with n-butyllithium in THF at -78°C, a process known as halogen-metal interchange. Alternatively, the organolithium reagent 21 can be generated directly by the reaction of 49 with an alkyllithium reagent in the presence or absence of a suitable complexing agent in THF at -78°C, e.g., sec-butyllithium/TMEDA (N,N,N',N'-tetramethylethylenediamine). In step 3, the organolithium reagent 51 was treated with anhydrous zinc chloride at -78°C and subsequently allowed to warm to ambient temperature. The organozinc reagent 18. was generated and used
Synthetic Scheme XXII shows the preparation of the 2-pyridinyl alkylating reagent 52 and the 3-pyridinyl alkylating 53 from 15. (Scheme VII) and 19 (Scheme VIII), respectively. In step 1, 15 and 19 were coupled with 1 using Snieckus conditions (Scheme XIII) or 48 using Negishi conditions [see E. Negishi, A. O. King, and N. Okukado, J. Org. Chem., 42, 1821 (1977)] to give 54 and 55,
respectively. In step 2, the coupled biaryl compounds 54 and 55 were brominated using NBS/AIBN to give the 2-pyridinyl alkylating reagent 52 and the 3-pyridinyl alkylating reagent 53, respectively.
Synthetic Scheme XXIII shows the preparation of 3- [[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-ones 20 (R5=CN4H) and 3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyllmethyl]-2H-imidazol-2-ones 31
(R5=CN4H) from the parent imidazol-2-ones 2 (prepared in Scheme IV, Scheme V, or Scheme VI). The imidazol-2-one 9 was first treated with a base, such as potassium t-butoxide, and subsequently with the alkylating reagent 22 or 53. (Scheme XXII) to give 3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-ones 30
(R5=CN4H) and 3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-ones 31 (R5=CN4H), respectively.
Scheme XXIV
Synthetic Scheme XXIV shows the preparation of 4-methylphenylboronic acid (56) from 4-bromotoluene. In step 1, the Grignard reagent was generated by the reaction of 4-bromotoluene with metallic magnesium in ether at reflux. In step 2, a THF solution of trimethoxyborane was cooled to -78° C and slowly treated with the Grignard reagent. In step 3, the boronic ester was hydrqlyzed with aqueous hydrochloric acid to give 4-methylphenylboronic acid (56).
Synthetic Scheme XXV shows the 8-step
preparation of the alkylating reagent 2-(4-bromomethyIphenyl)-3-cyanopyridine (57) from 2-amino-3- picoline (58) (Aldrich). In step 1, the aminopicoline 58 was converted to the bromopicoline 59 by reaction with bromine, concentrated hydrobromic acid, and sodium nitrite at 0°C. In step 2, the picoline 59 was oxidized with KMNO4 to give the corresponding carboxylic acid 60. In step 3, the acid 60 was reduced to the alcohol 61 with borane/THF. In step 4, the alcohol 61 was oxidized to the aldelyde 62 under Swern conditions or by using MnO2. In step 5, the aldehyde 62 was reacted with hydroxylamine to give the oxime 63. In step 6, the oxime 63 was converted to 2-bromo- 3-cyanopyridine (64) with acetic anhydride at reflux. In step 7, the nitrile 64 was coupled with 4- methylphenylboronic acid (56) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 3-cyano-2- (4- methyIphenyl)pyridine (65) . In step 8, 65 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 57.
Synthetic Scheme XXVI shows the 6-step
preparation of the alkylating reagent 3-(4-bromomethyIphenyl)-4-cyanopyridine (66) from 4-picoline (67) (Aldrich). In step 1, 4-picoline was brominated with bromine in fuming sulfuric acid at high temperatures to give 3-bromo-4-picoline (68 ) . In step 2, the picoline 68 was oxidized to the corresponding carboxylic acid 69 with KMnO4. In step 3, the acid 69 was first converted to its acid chloride with oxalyl chloride and subsequently treated with condensed ammonia to give the amide 70. In step 4, the amide 70 was converted to 3-bromo-4-cyanopyridine (71) by treatment with P2O5 at high temperatures. In step 5, the nitrile 71 was coupled with 4-methylphenylboronic acid (56) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 4-cyano-3-(4-methyIphenyl)pyridine (72). In step 6, 72 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 66.
Synthetic Scheme XXVII shows the 5-step
preparation of the alkylating reagent 4-(4-bromomethyIphenyl)-3-cyanopyridine (73) from 4-bromopyridine (74) (Aldrich). In step 1, the ortho-bromo carbanion was generated with LDA in THF at -78° C and reacted with anhydrous DMF to give 4-bromo-3-carboxaldehyde 75. In step 2, the aldehyde 75 was reacted with
hydroxylamine to give the oxime 76. In step 3, the oxime 76 was dehydrated with 1,1 -carbonyldiimidazole in methylene chloride at reflux to give 4-bromo-3-cyanopyridine (77). In step 4, the nitrile 77 was coupled with 4- methylphenylboronic acid (56) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 3-cyano-4-(4-methylphenyl)pridine (78). In step 5, 78 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 73.
Synthetic Scheme XXVIII shows the 4-step preparation of the alkylating reagent 2-cyano-3-(4-bromomethyIphenyl)pyridine (79) from 3-bromopyridine (80) (Aldrich). In step 1, the pyridine 22 was reacted with hydrogen peroxide in acetic acid at reflux to give the pyridine N-oxide 81. In step 2, the N-oxide 21 was
converted to 3-bromo-2-cyanopyridine (82) by reaction with trimethysilylcyanide and triethyl anine in acetonitrile at reflux. In step 3, the nitrile 82 was coupled with 4- methyIphenylboronic acid (56) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 2-cyano-3-(4-methyIphenyl) pyridine (83) . In step 4, 83 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 79.
Synthetic Scheme XXIX shows the preparation of 1,4,5-trisubstituted-1,3-dihydro-3-[[4-(2-cyano-3-pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 37 (R5=CN), 1,4,5-trisubstituted-1,3-dihydro-3-[[4-(3-cyano-4- pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 38 (R5=CN) ,
1,4,5-trisubstituted-1,3-dihydro-3-[[4-(4-cyano-3-pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 39 (R5=CN), and
1,4,5-trisubstituted-1,3,-dihydro-3-[[4-(3-cyano-2-pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 40 (R5=CN) from the parent 1,4, 5-trisubstituted-1,3-dihydro-2H-imidazol-2-ones 2 (prepared in Scheme IV, Scheme V, or Scheme VI). The imidazol-2-one 2 was first treated with a base, such as potassium t-butoxide, and subsequently with the alkylating reagents 79 (Scheme XXVIII), 73 (Scheme XXVII), 66 (Scheme XXVI) , and 57 (Scheme XXV) to give the alkylated products 37 (R5=CN), 22 (R5=CN, 22 (R5=CN), and 40 (R5=CN),
respectively.
The following Examples contain detailed descriptions of the methods of preparation of compounds of Formula I. These detailed descriptions fall within the scope of, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in degrees Centigrade, unless otherwise indicated.
1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyI]-2H-imidazoI-2-one Step 1 : Preparation of N-t-Boc-L-norleucine-N-methoxy-N-methylami de.
Under nitrogen, a stirred solution of 400 g (1.73 mol) of N-t-Boc-norleucine (BACHEM) and 193 g
(1.9 mol) of triethylamine (TEA) in 3000 mL of
dichloromethane (DCM) at -50 °C was treated with 258 g (1.9 mol) of isobutyl chlorformate. After 30 min, 203 g (2.08 mol) of solid N,O-dimethylhydroxylamine hydrochloride was added followed by 210.5 g (2.08 mol) of TEA at such a rate as to maintain the reaction temperature at -35 °C. The reaction was stirred at -15 °C for 1 h and then allowed to warm to ambient temperature and stir overnight. The reaction was washed with 1 M citric acid, NaHCO3 (sat), and brine. The solution was dried (Na2SO4) and concentrated in vacuo to give 499.3 g of crude product as a pale green oil: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H) , 1.28-1.38 (m, 4H), 1.43 (s, 9H), 1.49-1.57 (m, 1H) , 1.63-1.75 (m, 1H), 3.20 (s, 3H), 3.76 (s, 3H), 4.60-4.72 (m, 1H), 5.13 (d, J=8 Hz, 1H) .
Step 2A: Preparation of 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one: Method A. Under nitrogen, a stirred solution of 449 g of crude N-t-Boc-L-norleucine-N-methoxy-N-methylamide from Step 1 in 1350 mL of methylene chloride at 0 °C was treated with 1350 mL of trifluoroacetic acid (TFA). The reaction was allowed to warm to ambient temperature and stir. After 2 h, the reaction was concentrated in vacuo to give the TFA salt of L-norleucine-N-methoxy-N-methylamide as a viscous colorless oil: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H),
1.30-1.40 (m, 4H), 1.88 (t, J=7 Hz, 2H) , 3.25 (s, 3H), 3.75 (s, 3H), 4.35-4.46 (m, 1H), 7.55-7.76 (br s, 3H). The TFA salt was cooled to 0 °C and treated with aqueous sodium hydroxide until the pH was 10. The resulting solution was continuously extracted with ether for 24 h, continuously extracted with ether/DCM (3:1) for 24 h, and continuously extracted with ether/DCM (1:1) for 24 h. The organic layer was dried (Na2SO4) and concentrated in vacuo to give 245 g (83% from N-t-Boc-norleucine) as the monohydrate. Under nitrogen, a solution of this material in 100 mL of
chloroform at 0°C was slowly treated with 208 g (2.1 mol) of neat n-butylisocyanate over 15 min. The reaction was allowed to warm to ambient temperature and stir for 3 h. The reaction was concentrated in vacuo; purification by silica gel chromatography (Waters Prep-500A) using ethyl acetate gave 299.5 g as a colorless oil: NMR (CDCI3) δ 0.83-0.95 (m, 6H), 1.25-1.47 (m, 8H), 1.48-1.60 (m, 1H), 1.63-1.75 (m, 1H), 3.02-3.26 (m, 2H), 3.21 (s, 3H), 3.84 (s, 3H), 4.82-4.93 (m, 1H). Under nitrogen, 299 g
(1.09 mol) of this material was dissolved in 600 mL of anhydrous diethyl ether; the solution was cooled to -15°C and slowly treated with 720 mL (720 mmol) of a 1.0 M solution of lithium aluminum hydride (LAH) in ether. The reaction was allowed to warm to ambient temperature and stir overnight prior to the addition of 50 mL of ethyl acetate. A solution of 285 g (2 mol) of potassium
bisulfate in 1500 mL of water was added cautiously and the reaction stirred for 4 h. The reaction mixture was transferred to a separatory funnel and the phases
separated. The aqueous phase was extracted 8 times with additional ether. The combined ether extracts were washed 3 times each with 3N hydrochloric acid, saturated sodium bicarbonate, and brine. The ether extracts were then dried (MgSO4) and concentrated in vacuo to give 228 g (68% from N-t-Boc-norleucine) of 1,4-dibutyl-1,3-dihydro-2H-imidazol- 2-one as a viscous colorless oil which solidified on storage in the refrigerator: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 0.93 (t, J=7 Hz, 3H), 1.28-1.41 (m, 4H), 1.47-1.65 (m, 4H), 2.36 (td, J=7 and 1 Hz, 2H), 3.55 (t, J=7 Hz, 2H), 5.84 (t, J=1 Hz, 1H) , 9.78 (br s, 1H).
Step 2B : Preparation of 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one: Method B. Under nitrogen, a stirred solution of 67.8 g
(0.26 mol) of N-t-Boc-norleucine-N-methoxy-N-methylamide from Step 1 in 550 mL of anhydrous diethyl ether at 0 °C was treated with 145 mL (145 mmol) of a 1 M solution of lithium aluminum hydride (LAH) in ether over a 30 min period. The reaction was allowed to stir for an additional 30 min and then was quenched with the addition of 10 mL of ethyl acetate. The reaction was diluted with 1 L of cold water to which 63 g (0.46 mol) of potassium hydrogen sulfate had been added and the mixture stirred vigorously for 15 min. The phases were separated and the aqueous phase extracted 4 times with ether; the extracts were combined, washed 3 times with 3 N hydrochloric acid, once with saturated sodium bicarbonate, and once with brine, dried (Na2SO4) and concentrated in vacuo to give 47.6 g (84%) of N-t-Boc-L-norleucinal as a colorless waxy solid: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 1.34-1.41 (m, 4H), 1.46 (s, 9H), 1.55-1.64 (m, 1H), 1.80-1.95 (m, 1H) , 4.16-4.30 (m, 1H), 5.07-5.15
(m, 1H) , 9.59 (s, 1H). Under nitrogen, a stirred solution of 10.0 g (46.4 mmol) of this material in 10 mL of dioxane (anhydrous) at 0 °C was treated with 120 mL (480 mmol) of 4 N hydrogen chloride in dioxane over a 10 min period. The reaction was allowed to stir at 0 °C for an additional 20 min after the addition was complete and then
concentrated in vacuo. The residue was dissolved in 200 mL of chloroform and treated with 77.4 g (0.78 mol) of butyl isocyanate. The mixture was stirred at ambient temperature for 24 h, stirred at 40 °C for 24 h, and concentrated in vacuo. Purification of the reddish colored residue by silica gel chromatography (Harrison Chromatotron) using ethyl acetate/2-propanol (95:5) gave 160 mg (1.7% from N-t-Boc-L-norleucinal) of 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one as an yellowish oil: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 0.93 (t, J=7 Hz, 3H), 1.28-1.41 (m, 4H), 1.47-1.65 (m, 4H), 2.36 (td, J=7 and 1 Hz, 2H), 3.55 (t, J=7 Hz, 2H), 5.84 (t, J=1 Hz, 1H), 9.78 (br s, 1H); MS (FAB) m/e
(rel intensity) 197 (100), 153 (12), 141 (12), 125 (8), 111 (7). Step 2C: Preparation of 1,4-dibutyl-1,3-dihydro-2H- imidazol-2-one: Method C.
Under nitrogen, a solution of 27.0 g (125 mmol) of N-t-Boc-L-norleucinal from step 2B, 39.1 g (376 mmol) of 2,2-dimethyl-1,3-propanediol, and 1.18 g (6.2 mmol) of p-toluenesulfonic acid monohydrate in 220 mL of benzene was stirred at reflux for 22 h over a Dean-Stark trap. The reaction was cooled, diluted with 300 mL of ethyl acetate, washed sequentially with saturated sodium bicarbonate and brine, dried (Na2SO4), and concentrated in vacuo to give 38.27 g of crude ketal which was a red oil: NMR (CDCI3) δ 0.71 (s, 3H), 0.89 (t, J=7Hz 3H), 1.16 (s, 3H), 1.20-1.52 (m, 5H), 1.45 (s, 9H), 1.58-1.72 (m, 1H), 3.35-3.46
(m, 2H), 3.56-3.63 (m, 2H) , 4.43 (s, 1H), 4.66 (d, J=9Hz, 1H). Under nitrogen, a 38.2 g sample of the crude ketal was dissolved in 200 mL of methylene chloride; the solution was cooled to 0 °C and treated with 200 mL of trifluoracetic acid. The reaction was allowed to warm to ambient
temperature and stir for 2 h. Concentration in vacuo gave the crude TFA salt of the free amino ketal as a red viscous oil: NMR (CDCI3) δ 0.75 (s, 3H), 0.90 (t, J=7 Hz, 3H), 1.13 (s, 3H), 1.27-1.42 (m, 4H), 1.60-1.82 (m, 2H),
3.27-3.38 (m, 1H), 3.42-3.52 (m, 2H), 3.63-3.72 (m, 2H), 4.58 (d, J=3 Hz, 1H), 7.1-7.5 (br s, 3H). Under nitrogen, the crude TFA salt was redissolved in 100 mL of methylene chloride and treated with 264 g (2.66 mol) of butyl
isocyanate. The reaction was stirred at ambient
temperature for 17 h. The reaction was concentrated in vacuo to give the crude N-butyl urea of the ketal as a red oil. Purification of a small sample by silica gel
chromatography (Harrison Chromatotron) using ethyl
acetate/hexane (1:1) gave the pure -N-butyl urea as a pale yellow oil: NMR (CDCI3) δ 0.71 (s, 3H) , 0.89 (t, J=7 Hz, 3H), 0.92 (t, J=7 Hz, 3H), 1.16 (s, 3H), 1.23-1.54 (m, 9H), 1.61-1.75 (m, 1H), 3.09-3.21 (m, 2H), 3.37-3.46 (m, 2H), 3.56-3.64 (m, 2H), 3.68-3.79 (m, 1H), 4.32-4.47 (br s, 1H), 4.42 (d, J=3 Hz, 1H). Under nitrogen, a solution of the crude N-butyl urea ketal in 1 L of 1,4-dioxane was treated with 1 L of 6 N hydrochloric acid. The reaction was allowed to stir at ambient temperature for 16 h and then warmed to 60 °C and stirred for an additional 24 h. The reaction was concentrated in vacuo; the residue was treated with ethyl acetate and filtered. The ethyl acetate solution was dried (MgSO4) and concentrated in vacuo to give the crude product. Purification by silica gel chromatography (Waters Prep-500A) using methylene
chloride/2-propanol (95:5) gave 4.95 g (20% from N-t-Boc-L-norleucinal) of 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one as a pale yellow oil: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 0.93 (t, J=7 Hz, 3H) 1.28-1.41 (m, 4H) , 1.47-1.65 (m, 4H), 2.36 (td, J=7 and 1 Hz, 2H), 3.55 (t, J=7 Hz, 2H), 5.84 (t, J=1 Hz, 1H), 9.78 (br s, 1H).
Step 3 : Preparation of 2-bromo-5-picoline. A solution of 1500 mL (14 mol) of 48% hydrobromic acid was cooled to 10 °C and 300 g (2.8 mol) of 2-amino-5-picoline (Aldrich) was added slowly. The solution was maintained at or below 0 °C while 450 mL
(8.8 mol) of bromime was added dropwise. After the bromine addition was complete, a solution of 500 g (7.3 mol) of sodium nitrite in 1000 mL of water was added slowly over 6 h. The reaction pH was adjusted by the careful addition of 1500 mL (56 mol) of 50% sodium hydroxide at such a rate that the temperature was maintained below 30 °C. The product precipitated from the nearly colorless reaction mixture; filtration gave 450 g (94%) of 2-bromo-5-picoline as a yellow powder: mp 38-40 °C; NMR 7.27 (s, 1H) , 7.28 (s, 1H), 7.12 (br s, 1H). Step 4 : Preparation of 2-bromo-5-bromomethylpyridine.
A solution of 296.3 g (1.72 mol) of 2-bromo-5- picoline from step 3 in 6 L of carbon tetrachloride was treated with 306.5 g (1.72 mol) of N-bromosuccinimide (NBS) and 28.3 g (173 mmol) of azobisisobutyronitrile (AIBN). The reaction was stirred at reflux under nitrogen for 3 h, filtered, and concentrated in vacuo providing 476 g of crude 2-bromo-5-bromomethylpyridine as a brownish yellow solid (NMR indicates that this material is only 69% monobromomethyl product): NMR (CDCI3) δ 4.42 (s, 2H), 7.48 (d, J=9 Hz, 1H), 7.60 (dd, J=9 and 3 Hz, 1H) , 8.37 (d, J=3 Hz, 1H). Step 5: Preparation of 1,4-dibutyl-1,3-dihydro-3-[ (6 - bromo-3-pyridinyl)methyl]-2H-imidazol-2-one.
Under nitrogen, 138 mL (138 mmol) of 1.0 M potassium t-butoxide in THF was added to a stirred solution of 24.5 g (125 mmol) of 1,4-dibutylimidazol-2-one from step 2A in 370 mL of DMF at -30 °C at such a rate to maintain the solution temperature below -20 °C. After 10 min, 50 g
[138 mmol (69% purity)] of 2-bromo-5-bromomethylpyridine from step 4 and 2.7 g (18.1 mmol) of sodium iodide were added. The reaction was stirred at 0 °C for 2 h and then allowed to slowly warm to ambient temperature overnight. The reaction was partitioned between ethyl acetate and water; the organic layer was washed twice with brine and the combined aqueous phases were back-extracted with ethyl acetate. The ethyl acetate extractions were combined, dried (MgSO4), and concentrated in vacuo. Purification by silica gel chromatography (Waters Prep-500A) using
hexane/ethyl acetate (25:75) gave 33 g (73%) of 1,4-dibutyl-1,3-dihydro-3-[(6-bromo-3-pyridinyl)methyl]-2H-imdazol-2-one as a reddish-brown waxy solid: NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 0.95 (t, J=7 Hz, 3H), 1.25-1.51
(m, 6H), 1.57-1.71 (m, 2H), 2.22 (t, J=8 Hz, 2H), 3.60 (t, J=7 Hz, 2H) , 4. 80 (s, 2H) , 5. 90 (s, 1H) , 7.43 (d, J=9 Hz, 1H) , 7. 49 (dd, J=9 and 2 Hz, 1H) , 8.24 (d, J=2Hz, 1H) .
Step 6 : Preparation of 2-(N-triphenylmethyltetrazol-5- yl)phenylboronic acid.
A 64 g (350 mmol) sample of 2-bromobenzonitrile (Aldrich) was dissolved in 650 mL of xylene and treated with 22.75 g (350 mmol) of sodium azide and 95 mL
(350 mmol) of tributyltin chloride at reflux for 48 h. The reaction was filtered; the filtrate was treated with 50 mL of anhydrous tetrahydrofuran (THF) and 20 g (550 mmol) of hydrogen chloride. The reaction was stirred for 2 h;
filtration gave 59.6 g (76%) of 5-(2-bromophenyl)-1H-tetrazole: mp 178-180 °C; NMR (DMSO-d6) δ 7.50-7.64
(m, 2H), 7.67-7.74 (m, 1H), 7.83-7.91 (m, 1H). A 41.8 g (187 mmol) sample of this material was dissolved in 650 mL of methylene chloride and treated with 55.5 g (193 mmol) of triphenylmethyl chloride and 30 mL (220 mmol) of anhydrous triethylamine. The reaction was stirred overnight at reflux, cooled to ambient tempeature, washed with water, dried (MgSO4), and concentrated in vacuo.
Recrystallization from toluene/hexane gave 80.7 g (92%) of N-triphenylmethyl-5-(2-bromophenyl)-1H-tetrazole: mp 160-162 °C; NMR (CDCI3) δ 7.14-7.21 (m, 6H) , 7.26-7.45
(m, 11H), 7.70 (dd, J=8 and 1.5 Hz, 1H) , 7.89 (dd, J=7.5 and 2 Hz, 1H). A 34.05 g (73.0 mmol) sample of this material was dissolved in 1700 mL of THF under a nitrogen atmosphere and treated with 73 mmol of n-butyllithium in hexane. The reaction was allowed to stir for 17 min and then was treated with 24.9 mL (220 mmol) of trimethyl borate. The reaction was allowed to come to ambient temperature overnight while stirring, quenched with 10 mL of methanol, and concentrated in vacuo. The residue was dissolved in 1M NaOH and extracted with toluene to remove any unreacted starting material. The pH was adjusted to 6 with 6M HCl and the product extracted with toluene and dried (MgSO4). Hexane was added and the solution kept in the freezer overnight. Filtration provided 31.3 g (99%) of 2- (N-triphenylmethyltetrazol-5-yl) phenylboronic acid: NMR (CDCI3) δ 7.13-7.21 (m, 7H) , 7.33-7.42 (m, 8H), 7.49-7.55 (m, 2H), 8.15-8.19 (m, 1H), 8.21-8.26 (m, 1H).
Step 7: Preparation of 1 ,4-dibutyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyllmethyl]-2H-imidazol- 2-one.
A solution of 21.7 g (50.2 mmol) of 2- (N- triphenylmethyltetrazol-5-yl) phenylboronic acid from step 6 in 80 mL of ethanol and 130 mL of toluene was added to a mixture of 5 g (4 mmol) of tetrakis (triphenyIphosphine) Pd(0), 16.75 g (45.8 mmol) of 1,4-dibutyl-1,3-dihydro-3- [(6-bromo-3-pyridinyl)methyl]-2H-imidazol-2-one from step 5, 225 mL of toluene, 100 mL of 2 M sodium carbonate, and 150 mL of ethanol. The reaction mixture was heated to reflux and vigorously stirred under nitrogen for 14 h. The pH was adjusted to 6 with acetic acid and the reaction concentrated in vacuo. The product was purified by silica gel chromatography (Waters Prep-500A) using
2-propanol/methylene chloride (0-50%) followed by reverse phase chromatography (Waters Deltaprep-3000) using
acetonitrile/water (30-35:70-65) (0.05% TFA). The pure fractions (by analytical HPLC) were combined, the
acetonitrile removed in vacuo. and the water extracted 4 times with chloroform. The extracts were combined, dried (MgSθ4), and concentrated in vacuo. Recrystallization from ethyl acetate gave 8.5 g (43%) of colorless 1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl] methyl] -2H-imidazol-2-one as a colorless solid: mp 170-171 °C; NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 0.96 (t, J=7 Hz, 3H), 1.28-1.54 (m, 6H), 1.61-1.72 (m, 2H), 2.28 (t, J=8 Hz, 2H), 3.63 (t, J=7 Hz, 2H), 4.96 (s, 2H), 5.96 (s, 1H), 7.36 (d, J=9 Hz, 1H), 7.47-7.58 (m, 3H), 7.67 (dd, J=9 and 2 Hz, 1H), 8.06-8.13 (m, 1H) , 8.52 (d, J= 2 Hz, 1H);.MS (FAB) m/e (rel intensity) 432 (100), 404 (18), 237 (14), 209 (92), 180 (82); HRMS. Calc'd for M+H:
432.2512. Found: 432.2554. Anal. Calc'd for C24H29N7O: C, 66.80; H, 6.77; N, 22.72. Found: C, 66.59; H, 6.85; N, 22.57.
Example 2
1,4-dipropyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyI]-3- pyridinyl]methyI]-2H-imidazol-2-one
Step 1: Preparation of 1,4-dipropyl-1,3-dihydro-2H- imidazol-2-one.
Following General Synthetic Schemes III and IV, 1,4-dipropyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.92 (t, J=7 Hz, 3H), 0.93 (t, J=7 Hz, 3H), 1.57 (m, J=7 Hz, 2H), 1.67 (m, J=7 Hz, 2H), 2.34 (td, J=7 and 1 Hz, 2H), 3.52 (t, J=7 Hz, 2H), 5.86 (t, J=1 Hz, 1H), 10.06 (br s, 1H); MS (FAB) m/e (rel intensity) 169 (100), 153 (4), 139 (9), 127 (9); HRMS. Calc'd for M+H: 169.1341. Found 169.1346.
Step 2 : Preparation of 1,4-dipropyl-1,3-dihydro-3-[[ 6 - [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1,4-dipropyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.94 (t, J=7 Hz, 3H), 0.95 (t, J=7 Hz, 3H), 1.53 (m, J=7 Hz, 3H), 1.71 (m, J=7Hz, 2H), 2.27 (td, J=7 and 1 Hz, 2H), 3.60 (t, J=7 Hz, 2H), 4.95 (s, 2H), 5.97 (t, J=1 Hz, 1H), 7.33 (d, J=8 Hz, 1H), 7.47-7.57 (m, 3H), 7.64 (dd, J=8 and 2 Hz, 1H) , 8.04-8.11 (m, 1H), 8.52 (d, J=2Hz, 1H); MS (FAB) m/e (rel intensity) 404 (83), 376 (22), 347 (8), 237 (7), 209 (100), 180 (98); HRMS.
Calc'd for M+H: 404.2199. Found: 404.2177.
Example 3
1-propyl-4-isobutyI-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazoI-2-one
Step 1: Preparation of 1-propyl-4-isobutyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-propyl-4-isobutyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ0.91 (d, J=7 Hz, 6H) , 0.93 (t, J=7 Hz, 3H), 1.60-1.72 (m, 2H), 1.83 (m, J=7 Hz, 1H), 2.21 (d, J=7 Hz, 2H), 3.52 (t, J=7 Hz, 2H), 5.84-5.87 (m, 1H), 9.78 (br s, 1H); MS (FAB) m/e (rel intensity) 183 (100), 167
(4), 153 (2), 139 (15); HRMS. Calc'd for M+H: 183.1497.
Found: 183.1492.
Step 2 : Preparation of 1-propyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-Pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-propyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a
colorless solid: NMR (CDCI3) δ 0.90 (d, J=7 Hz, 6H), 0.95 (t, J=8 Hz, 3H), 1.62-1.78 (m, 3H), 2.16 (dd, J=7 and 1 Hz, 2H), 3.61 (t, J=7 Hz, 2H), 4.97 (s, 2H), 5.98 (s, 1H), 7.30 (d, J=8 Hz, 1H), 7.45-7.55 (m, 3H) , 7.60 (dd, J=8 and 2Hz, 1H), 8.01-8.07 (m, 1H), 8.49 (d, J=2Hz, 1H); MS (FAB) m/e (rel intensity) 418 (45), 390 (15), 375 (4), 361 (4), 237 (10), 209 (93), 195 (36), 180 (100); HRMS. Calc'd for M+H: 418.2355. Found: 418.2383.
Example 4
1-butyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyI]methyl]-2H-imidazol-2-one
Step 1: Preparation of 1-butyl-4-isobutyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-butyl-4-isobutyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δθ.91 (d, J=7 Hz, 6H), 0.94 (t, J=7 Hz, 3H), 1.28-1.41 (m, 2H), 1.57-1.68 (m, 2H), 1.75-1.87 (m, 1H), 2.21 (d, J=7 Hz, 2H), 3.55 (t, J=7 Hz, 2H), 5.86 (s, 1H), 8.86 (br s, 1H); MS (FAB) m/e (rel intensity) 197 (100), 181 (6), 173 (5), 167 (3), 153 (30), 141 (20), 125 (6), 111 (5); HRMS. Calc'd for M+H: 197.1654. Found:
197.1637.
Step 2 : Preparation of 1-butyl-4-isobutyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-butyl-4-isobutyl-l,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (DMSO-d6) δ 0.82 (d, J=6 Hz, 6H), 0.88 (t, J=7 Hz, 3H), 1.17-1.32 (m, 3H), 1.49-1.65 (m, 2H), 2.21 (d, J=7 Hz, 2H), 3.52 (t, J=7 Hz, 2H), 4.81 (s, 2H), 6.29 (s, 1H), 7.45 (d, J=8 Hz, 1H), 7.58-7.79 (m, 5H) , 8.25 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 432 (65), 404 (20), 375 (5), 237 (20), 209 (100), 194 (30), 180 (65);
HRMS. Calc'd for M+H: 432.2512. Found: 432.2562.
Example 5
1-butyl-4-isopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyI]methyI]-2H-imidazoI-2-one
Step 1: preparation of 1-butyl-4-isopentyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-butyl-4-isopentyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCl3) δ0.90 (d, J=7 Hz, 6H), 0.93 (t, J=7 Hz, 3H), 1.26-1.67 (m, 7H), 2.35 (t, J=7 Hz, 2H), 3.54 (t, J=7 Hz, 2H), 5.83 (br s, 1H), 9.40 (br s, 1H); MS (FAB) m/e (rel intensity) 211 (100), 195 (8), 167 (15), 153 (25), 132 (8), 111 (20); HRMS. Calc'd for M+H: 211.1810. Found:
211.1802.
Step 2 : Preparation of 1-butyl-4-isopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-butyl-4-isopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.87 (d, J=7 Hz, 6H), 0.95 (t, J=7 Hz, 3H), 1.30-1.43 (m, 4H), 1.50-1.72 (m, 3H), 2.28 (t, J=8 Hz, 2H), 3.62 (t, J=7 Hz, 2H), 4.97 (s, 2H), 5.95 (s, 1H), 7.32 (d, J=9 Hz, 1H), 7.46-7.56 (m, 3H), 7.69 (dd, J=9 and 2Hz, 1H), 7.97-8.03 (m, 1H) , 8.48 (br s, 1H); MS (FAB) m/e (rel intensity) 446 (100), 418 (25), 237 (15), 209 (75), 180 (65); HRMS. Calc'd for M+H: 446.2669. Found : 446.2654.
Example 6
1-butyI-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazoI-5-yl)phenyI]-3- pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-butyl-4-pentyl-1,3-dihydro-2H- imidazol-z-one.
Following General Synthetic Schemes III and IV, 1-butyl-4-pentyl-1,3,-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 0.92 (t, J=7 Hz, 3H), 1.24-1.43 (m, 6H), 1.47-1.70 (m, 4H), 2.35 (t, J=7 Hz, 2H), 3.55 (t, J=7 Hz, 2H), 5.82-5.87 (m, 1H), 9.60 (br s, 1H); MS (FAB) m/e (rel intensity) 211 (100), 155 (15); HRMS. Calc'd for M+H: 211.1810. Found: 211.1796.
Step 2 : Preparation of 1-butyl-4-pentyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pγridinyl]methγl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-butyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 176-177° C; NMR (CDCl 3) δθ.87 (t, J=7 Hz, 3H), 0.96 (t, J=8 Hz, 3H), 1.24-1.43 (m, 6H), 1.45-1.56 (m, 2H), 1.61-1.72 (m, 2H), 2.29 (t, J=8 Hz, 2H), 3.63 (t. J=8 Hz, 2H), 4.96 (s, 2H), 5.97 (s, 1H), 7.45 (d, J=8 Hz, 1H), 7.50-7.62 (m, 3H), 7.79 (dd, J=8 and 2 Hz, 1H), 8.11-8.18 (m, 1H), 8.55 (d, J=2 Hz); MS (FAB) m/e (rel
intensity) 446 (76), 418 (27), 403 (8), 390 (8), 389 (8), 237 (25), 209 (100), 194 (35), 180 (79);HRMS. Calc'd for M+H: 446.2668. Found: 446.2677.
Example 7
1-butyl-4-cyclohexyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyI]-3- pyridinyI]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-butyl-4-cyclohexyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-butyl-4-cyclohexyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.93 (t, J=7 Hz, 3H), 1.12-1.42 (m, 8H), 1.55-1.84 (m, 8H), 1.84-1.95 (m, 2H), 2.25-2.38 (m, 1H), 3.54 (t, J=7 Hz, 2H), 5.79 (q, J=1 Hz, 1H), 8.97 (br s, 1H); MS (FAB) m/e (rel intensity) 223 (100). HRMS.
Calc'd for M+H: 223.1810. Found: 223.1811. Step 2 : Preparation of 1-butyl-4-cyclohexyl-1,3-dihydro- 3-[[6-[2-(1H-tetrazol-5-yl)Phenyl]-3-Pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-butyl-4-cyclohexyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl) phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a
colorless solid: NMR (CDCI3) δ 0.96 (t, J=7 Hz, 3H), 1.12-1.45 (m, 8H), 1.57-1.89 (m, 8H), 2.20-2.23 (m, 1H), 3.62 (t, J=7 Hz, 2H), 5.02 (s, 2H), 5.96 (s, 1H), 7.53-7.68 (m, 4H), 8.03 (d, J=8 Hz, 1H), 8.12-8.19 (m, 1H), 8.59 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 458 (70), 430 (20), 222 (20); HRMS. Calc'd for M+H: 458.2668. Found: 458.2676.
Example 8
1-butyl-4-cyclopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyI]-2H-imidazoI-2-one Step 1 : Preparation of 1-butyl-4-cyclopentyl-1,3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-butyl-4-cyclopentyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.94 (t, J=7 Hz, 3H), 1.17-1.42 (m, 4H), 1.42-1.80 (m, 6H), 1.89-2.01 (m, 2H), 2.64-2.93 (m,
1H), 3.55 (t, J=7 Hz, 2H), 5.84 (q, J=1 Hz, 1H), 9.90 (br s, 1H); MS (FAB) m/e (rel intensity) 209 (100), 153 (10);
HRMS. Calc'd for M+H: 209.1654. Found: 209.1725.
Step 2 : Preparation of 1-butyl-4-cyclopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-butyl-4-cyclopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a
colorless solid: mp 195-196° C (dec); NMR (CDCI3) δθ.95 (t,J=8 Hz, 3H), 1.30-1.49 (m, 4H), 1.53-1.77 (m, 6H), 1.83-1.95 (m, 2H), 2.61-2.74 (m, 1H), 3.62 (t, J=8 Hz, 2H) , 5.01 (s, 2H), 5.97 (d, J=1 Hz, 1H), 7.37 (d, J=8 Hz, 1H), 7.48-7.58 (m, 3H), 7.70 (dd, J=8 and 2 Hz, 1H), 8.03-8.10 (m, 1H), 8.52 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 444 (57), 416 (17), 237 (20), 209 (100), 194 (34), 180 (70); HRMS. Calc'd for M+H: 444.2512. Found: 444.2487.
Example 9
1-butyI-4-(2-cyclopropylethyI)-1,3-dihydro-3-[[6-[2-(1H-tetrazoI-5- yl)phenyl]-3-pyridinyI]methyl]-2H-iinidazoI-2-one
Step 1 : Preparation of 1-butyl-4-(2-cyclopropylethyl)- 1,3-dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-butyl-4-(2-cyclopropylethyl)-1,3-dihydro-2H-imidazol-2- one was prepared: NMR (CDCI3) δ 0.00-0.07 (m, 2H), 0.37-0.45 (m, 2H), 0.61-0.76 (m, 1H), 0.92 (t, J=7 Hz, 3H), 1.28-1.48 (m, 4H), 1.55-1.67 (m, 2H), 2.46 (t, J=7 Hz, 2H), 3.54 (t, J=7 Hz, 2H) , 5.82-5.86 (m, 1H), 10.0 (br s, 1H); MS (FAB) m/e (rel intensity) 209 (100), 193 (4), 179 (3), 165 (8), 153 (30), 137 (4), 123 (4), 111 (10); HRMS. Calc'd for M+H: 209.1654. Found: 209.1721.
Step 2 : Preparation of 1-butyl-4-(2-cyclopropylethyl) - 1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-butyl-4-(2-cyclopropylethyl)-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.00-0.07 (m, 2H), 0.40- 0.47 (m, 2H), 0.63-0.77 (m, 1H), 0.94 (t, J=7 Hz, 3H), 1.03-1.45 (m, 4H), 1.65 (m, J=7 Hz, 2H), 2.40 (t, J=7 Hz, 2H), 3.62 (t, J=7 Hz, 2H), 4.99 (s, 2H), 5.97 (s, 1H), 7.35 (d, J=8 Hz, 1H), 7.48-7.56 (m, 3H), 7.74 (dd, J=8 and 2 Hz, 1H), 7.97-8.04 (m, 1H), 8.50 (d, J=1 Hz, 1H); MS (FAB) m/e (rel intensity) 444 (100), 416 (16), 401 (9), 388 (5), 237 (14), 209 (33), 194 (16), 180 (35); HRMS. Calc'd for M+H: 444.2512. Found: 444.2513.
Example 10
1-methyI-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazoI-5-yl)phenyI]-3- pyridinyl]methyI]-2H-imidazol-2-one
Step 1 : Preparation of 1-methyl-4-butyl-1 , 3 , -dihydro-2H- imidazol-2-c
Following General Synthetic Schemes III and IV,
1-methyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was
prepared: NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 1.26-1.40 (m, 2H), 1.45-1.56 (m, 2H), 2.34 (t, J=8 Hz, 2H), 3.18 (s, 3H), 5.79-5.83 (m, 1H), 10.18 (br s, 1H).
Step 2 : Preparation of 1-methyl-4-butyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-Pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to
1-methyl-4-butyl-1,3,-dihydro-3-[[6-[2(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 184-185° C (dec); NMR (CDCI3) δ 0.88 (t, J=8 Hz, 3H), 1.28-1.54 (m, 4H), 2.29 (t, J=8 Hz, 2H), 3.28 (s, 3H), 4.97 (s, 1H), 5.95 (s, 1H), 7.38 (d, J=8 Hz, 1H), 7.47-7.59 (m, 3H), 7.74 (dd, J=8 and 2 Hz, 1H), 8.04-8.11 (m, 1H), 8.53 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 390 (100), 362 (12), 237 (17), 209 (46), 194 (18), 180 (40); HRMS. Calc'd for M+H: 390.2042. Found 390.2021.
Example 11
1-ethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazoI-5-yl)phenyl]-3- pyridinyl]methyI]-2H-imidazol-2-one
Step 1 : Preparation of 1-ethyl-4-butyl-1 , 3-dihγdro-2H- imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-ethyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 1.24-1.41 (m, 2H), 1.27 (t, J=8 Hz, 3H), 1.44-1.58 (m, 2H), 2.35 (t, J=8 Hz, 2H), 3.59 (q, J=8 Hz, 2H), 5.83-5.86 (m, 1H), 10.13 (br s, 1H); MS (FAB) m/e (rel intensity) 169 (100), 141 (4), 139 (5), 125 (17); HRMS. Calc'd for M+H: 169.1341. Found: 169.1365.
Step 2 : Preparation of 1-ethyl-1-butyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to
1-ethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 205° C (dec); NMR (CDCI3) δ 0.89 (t,J=7 Hz, 3H), 1.27-1.55 (m, 4H), 1.30 (t, J=8 Hz, 3H), 2.31 (t, J=8 Hz, 2H), 3.69 (q, J=8 Hz, 2H), 4.98 (s, 2H), 6.00 (t, J=1 Hz, 1H), 7.46 (d, J=8 Hz, 1H), 7.52-7.62 (m, 3H), 7.84 (dd, J=8 and 2 Hz, 1H) , 8.08-8.15 (m, 1H) , 8.55 (d, J=2 Hz, 1H) ; MS (FAB) m/e (rel intensity) 404 (93), 376 (20), 237 (18), 209 (100), 194 (30), 180 (80), 168 (26); HRMS. Calc'd for M+H: 404.2199. Found: 404.2257.
Example 12
1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazoI-2-one Step1: Preparation of 1-propyl-4-butyl-1,3-dihydro-2H- imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-propyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was
prepared: NMR (CDCl3) δ 0.87 (t, J=7 Hz, 3H), 0.90 (t, J=7 Hz, 3H), 1.25-1.39 (m, 2H), 1.44-1.56 (m, 2H), 1.58-1.61 (m, 2H), 2.34 (td, J=8 and 1 Hz, 2H), 3.49 (t, J=8 Hz, 2H), 5.82 (t, J=1 Hz, 1H), 10.33 (br s, 1H); MS (FAB) m/e (rel intensity) 183 (100), 141 (13), 139 (15); HRMS. Calc'd for M+H: 183.1497. Found 183.1497. Steps 2 : Preparation of 1-propyl-4-butyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from .Step 1 was converted to 1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 164-165° C; NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 0.94 (t, J=7 Hz, 3H) , 1.29-1.55 (m, 4H), 1.63-1.77 (m, 2H), 2.30 (td, J=8 and 1 Hz, 2H), 3.60 (t, J=8 Hz, 2H), A . 91 (s, 1H), 5.98 (t, J=1 Hz, 1H), 7.43 (d, J=8 Hz, 1H), 7.50-7.61 (m, 3H), 7.80 (dd, J=8 and 2 Hz, 1H), 8.05-8.12 (m, 1H), 8.53 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 418 (100), 390 (12), 209 (20), 180 (21); HRMS. Calc'd for M+H: 418.2355. Found: 418.2312.
Example 13
1-isobutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyI]-2H-imidazol-2-one
Step 1: Preparation of 1-isobutyl-4-butyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-isobutyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 0.92 (d, J=7 Hz, 6H), 1.27-1.41 (m, 2H), 1.46-1.58 (m, 2H) 1.97 (m, J=7 Hz, 1H), 2.36 (td, J=8 and 1 Hz, 2H), 3.36 (d, J=8 Hz, 2H), 5.84 (t, J=1 Hz, 1H) , 9.86 (br s, 1H); MS (FAB) m/e (rel intensity) 197 (100), 141 (22); HRMS. Calc'd for M+H: 197.1654. Found: 197.1635. Step 2: Preparation of 1-isobutyl-4-butyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to
1-isobutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 160.0-161.5° C; NMR (CDCI3) δ 0.87 (t, J=7 Hz, 3H), 0.92 (d, J=7 Hz, 6H), 1.27-1.53 (m, 4H), 1.99 (m, J=7 Hz, 1H), 2.28 (t, J=8 Hz, 2H), 3.43 (d, J=7 Hz, 2H), 4.97 (s, 2H), 5.93 (s, 1H) , 7.27 (d, J=8 Hz, 1H), 7.43-7.52 (m, 3H), 7.65 (dd, J=8 and 2 Hz, 1H) , 7.91-7.98 (m, 1H), 8.45 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 432 (100), 404 (15), 209 (23), 180 (25); HRMS. Calc'd for M+H: 432.2512. Found: 432.2571.
Example 14
1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyI]-2H-imidazoI-2-one
Step 1 : Preparation of 1-isopentyl-4-butyl-1,3-dihγdro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV,
1-isopentyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 0.92 (d, J=7 Hz, 6H), 1.26-1.40 (m, 2H), 1.46-1.66 (m, 6H), 2.35 (td,
J=8 and 1 Hz, 2H), 3.55 (t, J=8 Hz, 2H), 5.82 (t, J=1 Hz, 1H), 10.41 (br s, 1H); MS (FAB) m/e (rel intensity) 211 (100), 141 (13), 111 (14); HRMS. Calc'd for M+H: 211.1810. Found: 211.1800. Step 2 : Preparation of 1-isopentyl-4-butyl-1,3-dihydro- 3-[[6-[2-(1H-tetrazol-5-yl)Phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from. Step 1 was converted to
1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 168.5-170.0° C; NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 0.95 (d, J=6 Hz, 6H), 1.27-1.67 (m, 7H), 2.38 (t, J=8 Hz, 2H), 3.63 (t, J=8 Hz, 2H), 4.95 (s, 2H), 5.96
(s, 1H), 7.32 (d, J=8 Hz, 1H) , 7.44-7.56 (m, 3H), 7.69 (dd,J=8 and 1 Hz, 1H), 8.00 (td, J=3 and 1 Hz, 1H), 8.47 (br s, 1H); MS (FAB) m/e (rel intensity) 446 (100), 418 (21), 403 (8), 237 (12), 209 (30), 194 (13), 180 (28); HRMS. Calc'd for M+H: 446.2662. Found: 446.2668.
Example 15
1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yI)phenyl]-3- pyridinyI]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-pentyl-4-butyl-1 , 3-dihydro-2H- imidazol-2-one .
Following General Synthetic Schemes III and IV, 1-pentyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was
prepared: NMR (CDCI3) δ 0.87 (t, J=7 Hz, 3H), 0.89 (t, J=7 Hz, 3H), 1.21-1.39 (m, 6H), 1.42-1.69 (m, 4H) , 2.34 (td, J=8 and 1 Hz, 2H), 3.52 (t, J=8 Hz, 2H), 5.82 (t, J=1 Hz, 1H), 10.45 (br s, 1H); MS (FAB) m/e (rel intensity) 211 (100), 141 (19); HRMS. Calc'd for M+H: 211.1810. Found: 211.1792. Step 2 : Preparation of 1-pentyl-4-butyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 162-164° C; NMR (CDCI3) δ 0.87 (t, J=7 Hz, 3H), 0.89 (t, J=7 Hz, 3H), 1.23-1.41 (m, 6H), 1.42-1.54 (m, 2H), 1.61-1.73 (m, 2H), 2.39 (t, J=8 Hz, 2H), 3.61 (t, J=8 Hz, 2H), 4.96 (s, 2H), 5.96 (s, 1H), 7.39 (d, J=8 Hz, 1H), 7.48-7.58 (m, 3H), 7.76 (dd, J=8 and 1 Hz, 1H), 8.02- 8.09 (m, 1H), 8.51 (d, J=1 Hz, 1H); MS (FAB) m/e (rel intensity) 446 (58), 418 (22), 237 (18), 209 (100), 194 (29), 180 (55); HRMS. Calc'd for M+H: 446.2668. Found: 446.2683.
Example 16
1-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyI]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-isopropyl-4-butyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV,
1-isopropyl-4-butyl-1, 3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.88 (t, J=8 Hz, 3H), 1.24 (d, J=7 Hz, 6H), 1.28-1.39 (m, 2H), 1.43-1.59 (m, 2H), 2.34 (td,
J=8 and 1 Hz, 2H), 4.34 (m, J=7 Hz, 1H), 5.87 (t, J=1 Hz, 1H) , 10.39 (br s, 1H); MS (FAB) m/e (rel intensity) 183 (100), 141 (48), 139 (37); HRMS. Calc'd for M+H: 183.1497. Found: 183.1472. Step 2 : Preparation of 1-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-Pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to
1-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a
colorless solid: NMR (CDCI3) δ 0.87 (t, J=7 Hz, 3H), 1.30 (d, J=7 Hz, 6H), 1.22-1.41 (m, 2H), 1.41-1.53 (m, 2H), 2.28 (t, J=8 Hz, 2H), 4.42 (m, J=7 Hz, 1H), 4.96 (s, 1H), 6.00 (s, 1H), 7.27 (d, J=8 Hz, 1H), 7.43-7.52 (m, 3H) , 7.65 (dd, J=8 and 2 Hz, 1H), 7.89-7.96 (m, 1H), 8.44 (d, J=2 Hz, 1H);
MS (FAB) m/e (rel intensity) 418 (100), 390 (35), 375 (10), 361 (10), 237 (15), 209 (100), 193 (30), 180 (90); HRMS.
Calc'd for M+H: 418.2355. Found: 418.2381.
Example 17
1-tertbutyI-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyI]-3- pyridinyI]methyl]-2H-imidazoI-2-one
Step 1 : Preparation of 1-tertbutyl-4-butyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-tertbutyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.90 (t, J=8 Hz, 3H), 1.27-1.38 (m, 2H), 1.45-1.59 (m, 2H), 1.51 (s, 9H), 2.32 (td, J=8 and 1 Hz, 2H), 5.94 (t, J=1 Hz, 1H) , 9.86 (br s, 1H); MS (FAB) m/e (rel intensity) 197 (73), 141 (100); HRMS. Calc'd for M+H: 197.1654. Found: 197.1670.
Step 2 : Preparation of 1-tertbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-Pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV, the imidazol-2-one from Step 1 was converted to 1-tertbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tertazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 1.22- 1.59 (m, 4H), 1.55 (s, 9H) , 2.27 (t, J=8 Hz, 2H), 4.90 (s, 2H), 6.06 (s, 1H), 7.37 (d, J=8 Hz, 1H), 7.48-7.58 (m, 3H), 7.71 (dd, J=8 and 2 Hz, 1H) , 7.99-8.06 (m, 1H), 8.48 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 432 (100), 404 (20), 389 (5), 375 (15), 348 (10), 237 (15), 209 (95), 194 (25), 180 (55); HRMS. Calc'd for M+H: 432.2512. Found: 432.2578.
Example 18
1-neopentyl-4-butyl-1,3-dihydro-34[6-[2-(1H-tetrazol-5-yI)phenyI]-3- pyridinyI]methyI]-2H-imidazoI-2-one Step 1 : Preparation of 1-neopentyl-4-butyl-1,3-dihydro- 2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-neopentyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.87 (t, J=8 Hz, 3H), 0.92 (s, 9H), 1.23-1.37 (m, 2H), 1.43-1.55 (m, 2H), 2.31 (td, J=8 and 1 Hz, 2H), 3.31 (s, 2H), 5.80 (t, J=1 Hz, 1H), 10.62 (br s, 1H); MS (FAB) m/e (rel intensity) 211 (100), 141 (22);
HRMS. Calc'd for M+H: 211.1810. Found: 211.1745.
Step 2 : Preparation of 1-neopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-neopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a
colorless solid: mp 194.5-195.0° C; NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 0.97 (s, 9H), 1.29-1.55 (m, 4H), 2.31 (t, J=8 Hz, 2H), 3.41 (s, 2H), 4.98 (s, 2H), 5.96 (s, 1H), 7.43 (d, J=8 Hz, 1H), 7.50-7.59 (m, 3H), 7.82 (dd, J=8 and 2 Hz, 1H), 8.06-8.13 (m, 1H) , 8.54 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 446 (100), 418 (17), 403 (6), 237 (11), 209 (27), 194 (11), 180 (27); HRMS. Calc'd for M+H: 446.2668. Found: 446.2647.
Example 19
1-(3,3-dimethyIbutyl)-4-butyI-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyI]methyl]-2H-imidazoI-2-one Step 1: Preparation of 1-(3,3-dimethylbutyl)-4-butyl- 1 ,3-dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(3,3-dimethylbutyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.92 (t, J=8 Hz, 3H) , 0.96 (s, 9H) , 1.28-1.42 (m, 2H), 1.48-1,59 (m, 4H), 2.38 (td, J=8 and 1 Hz, 2H), 3.54-3.62 (m, 2H), 5.58 (t, J=1 Hz, 1H), 9.70 (br s, 1H); MS (FAB) m/e (rel intensity) 225 (100), 141 (13); HRMS. Calc'd for M+H: 225.1967. Found: 225.1897. Step 2 : Preparation of 1-(3,3-dimethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(3,3-dimethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.89 (t, J=8 Hz, 3H), 0.97 (s, 9H), 1.29-1.54 (m, 4H), 1.55-1.63 (m, 2H), 2.30 (t, J=8 Hz, 2H), 3.60-3.68 (m, 2H), 4.95 (s, 2H), 5.97 (s, 1H), 7.38 (d, J=8 Hz, 1H), 7.48-7.59 (m, 3H), 7.75 (dd, J=8 and 2 Hz, 1H), 8.02-8.09 (m, 1H), 8.51 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 460 (47), 432 (23), 237 (18), 209 (100), 194 (32), 180 (74); HRMS. Calc'd for M+H: 460.2825. Found: 460.2821.
Example 20
1-(2-ethyIbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yI)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-(2-ethylbutyl)-4-butyl-1,3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2-ethylbutyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.80-0.91 (m, 9H), 1.18-1.37 (m, 6H), 1.41-1.64 (m, 3H), 2.32 (td, J=8 and 1 Hz, 2H), 3.41 (d, J=8 Hz, 2H), 5.72 (t, J=1 Hz, 1H) , 10.60 (br s, 1H); MS (FAB) m/e (rel intensity) 225 (100), 141 (22); HRMS. Calc'd for M+H: 225.1967. Found: 225.1971.
Step 2 : Preparation of 1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 174-176° C (dec); NMR (CDCI3) δ 0.85-0.96 (m, 9H), 1.27-1.40 (m, 6H), 1.41-1.55 (m, 2H), 1.59-1.70 (m, 1H), 2.30 (t, J=8 Hz, 2H), 3.53 (d, J=8 Hz, 2H), 4.97 (s, 2H), 5.94 (s, 1H), 7.39 (d, J=8 Hz, 1H), 7.48-7.58 (m, 3H), 7.75 (dd, J=8 and 2 Hz, 1H) , 8.03-8.09 im, 1H), 8.51 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 460 (73), 432 (25), 237 (23), 209 (100), 194 (29), 180 (61); HRMS. Calc'd for M+H: 460.2825. Found: 460.2862.
Example 2
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyI]methyl]-2H-imidazoI-2-one
Preparation of 1-cyclohexyl-4-butyl-1 , 3-dihydro - 2H-imidaz ol-2-one.
Following General Synthetic Schemnes III and IV,
1-cyclohexyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 1.05-1.24 (m, 2H), 1.26-1.46 (m, 4H), 1.47-1.58 (m, 2H), 1.63-1.76 (m, 2H), 1.78-1.96 (m, 4H), 2.36 (td, J=8 and 1 Hz, 2H), 3.87-4.00 (m, 1H), 5.89 (t, J=1 Hz, 1H), 9.82 (br s, 1H); MS (FAB) m/e (rel intensity) 223 (100), 141 (53); HRMS. Calc'd for M+H: 223.1810. Found: 223.1738. Step 2 : Preparation of 1-cyclohexyl-4-butyl-1,3-dihydro- 3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-cyclohexyl-4-butyl-1, 3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 202-203° C (dec); NMR (CDCI3) δ 0.89 (t, J=8 Hz, 3H), 1.08-1.24 (m, 2H), 1.26-1.54 (m, 7H), 1.66-1.76 (m, 1H), 1.77-2.00 (m, 4H), 2.28 (t, J=8 Hz, 2H), 3.95-4.07 (m, 1H), 4.97 (s, 2H), 6.00 (s, 1H), 7.32 (d,J=8 Hz, 1H), 7.45-7.55 (m, 3H), 7.69 (dd, J=8 and 2 Hz, 1H), 7.96-8.04 (m, 1H), 8.47 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 458 (56), 430 (19), 237 (19), 208 (100), 194 (36), 180 (76); HRMS. Calc'd for M+H: 458.2668. Found: 458.2732.
Example 22
1-(2-cyclopropylethyI)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1- (2-cyclopropylethyl) -4-butyl - 1 , 3-dihydro-2H-imidazol-2-one .
Following General Synthetic Schemes III and IV or XXIII, 1-(2-cyclopropylethyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.00-0.06 (m, 2H), 0.38-0.46 (m, 2H), 0.59-0.73 (m, 1H), 0.89 (t, J=8 Hz, 3H), 1.16-1.40 (m, 4H), 1.44-1.57 (m, 4H), 2.34 (td, J=8 and 1 Hz, 2H), 3.62 (t, J=7 Hz, 2H), 5.84 (t, J=1 Hz, 1H), 10.38 (br s, 1H); MS (FAB) m/e (rel intensity) 209 (100), 153 (43), 141 (16); HRMS. Calc's for M+H: 209.1654. Found: 209.1695.
Step 2 : Preparation of 1-(2-cyclopropylethyl)-4-butyl-1,3-dihydro-3-[ [6- [2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-cyclopropylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 182-183° C; NMR (CDCI3) δ 0.04- 0.11 (m, 2H), 0.43-0.51 (m, 2H), 0.60-0.76 (m, 1H), 0.91 (t, J=7 Hz, 3H), 1.30-1.44 (m, 2H), 1.45-1.64 (m, 4H), 2.36 (t, J=7 Hz, 2H), 3.72 (t, J=7 Hz, 2H), 5.04 (s, 2H), 6.01 (s, 1H), 7.57-7.68 (m, 4H), 8.11 (d, J=7 Hz, 1H), 8.15-8.20 (m, 1H), 8.64 (s, 1H); MS (FAB) m/e (rel intensity) 237 (24), 209 (53), 192 (18), 180 (43); HRMS. Calc'd for M+H: 444.2512. Found: 444.2509.
Example 23
1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-cyclopentyl-4-butyl-1 , 3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV,
1-cyclopentyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.91 (t, J=8 Hz, 3H), 1.29-1.42 (m, 2H), 1.48-1.85 (m, 10H), 1.98-2.12 (m, 2H), 2.47 (td, J=8 and 1 Hz, 2H), 4.44-4.57 (m, 1H), 5.88 (t, J=1 Hz, 1H), 10.22 (br s, 1H); MS (FAB) m/e (rel intensity) 209 (100), 141 (43); HRMS. Calc'd for M+H: 209.1654. Found: 209.1656.
Step 2 : Preparation of 1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to
1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 1.30-1.40 (m, 2H), 1.41-1.52 (m, 2H), 1.56-1.86 (m, 6H), 2.02-2.14 (m, 2H), 2.27 (t, J=7 Hz, 2H), 4.55 (m, J=7 Hz, 1H), 4.97 (s, 2H), 5.98 (s, 1H), 7.27 (d, J=8 Hz, 1H), 7.44-7.54 (m, 3H), 7.62 (dd, J=8 and 2 Hz, 1H), 7.98-8.05 (m, 1H), 8.48 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 444 (100), 416 (12), 401 (6), 387 (4), 233 (13), 209 (22), 194 (12), 180 (25); HRMS. Calc'd for M+H: 444.2512. Found:
444.2518.
Example 24
1-cyclopentylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyI]-3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-cyclopentylmethyl-4-butyl-1,3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-cyclopentylmethyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.89 (t, J=8 Hz, 3H), 1.16-1.39 (m, 4H), 1.44-1.77 (m, 8H) , 2.21 (m, J=8 Hz, 1H) , 2.45 (t, J=8 Hz, 2H), 3.46 (d, J=8 Hz, 2H), 5.81-5.85 (m, 1H), 10.33 (br s, 1H); MS (FAB) m/e (rel intensity) 223 (100), 141 (30); HRMS. Calc'd for M+H: 223.1810. Found: 223.1767.
Step 2 : Preparation of 1-cyclopentylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to
1-cyclopentylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 204° C (dec); NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 1.19-1.70 (m, 12H), 2.19-2.34 (m, 3H), 3.55 (d, J=8 Hz, 2H), 4.98 (s, 2H), 5.98 (t, J=1 Hz, 1H), 7.44 (d, J=8 Hz, 1H), 7.50-7.61 (m, 3H), 7.81 (dd, J=8 and 2 Hz, 1H), 8.07-8.13 (m, 1H), 8.53 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 458 (65), 430 (22), 237 (24), 209 (100), 194 (30), 180 (65); HRMS. Calc'd for M+H: 458.2668. Found: 458.2699.
Example 25
1-[2-(2-thienyI)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyI]-3-pyridinyl]methyI]-2H-imidazol-2-one
Step 1 : Preparation of 1-[2-(2-thienyl)ethyl]-4-butyl- 1,3-dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-[2-(2-thienyl)ethyl]-4-butyl-1,3-dihydro-2H-imidazol-2- one was prepared: NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 1.26- 1.40 (m, 2H), 1.44-1.56 (m, 2H), 2.32 (t, J=7 Hz, 2H), 3.16 (t, J=7 Hz, 2H), 3.82 ( t, J=7 Hz, 2H), 5.69-5.75 (m, 1H), 6.80-6.83 (m, 1H), 6.90-6.95 (m, 1H), 7.12-7.17 (m, 1H), 10.02 (br s, 1H); MS (FAB) m/e (rel intensity) 251 (90), 111 (100); HRMS. Calc'd for M+H: 251.1218. Found: 251.1209. Step 2 : Preparation of 1-[2-(2-thienyl)ethyl]-4-butyl- 1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-[2-(2-thienyl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 137-138° C; NMR (CDCI3) δ 0.86 (t, J=7 Hz, 3H), 1.23-1.36 (m, 2H), 1.37-1.51 (m, 2H), 2.26 (td, J=8 and 1 Hz, 2H), 3.23 (t, J=8 Hz, 2H), 3.93 (t, J=8 Hz, 2H), 4.93 (s, 2H), 5.84 (t, J=1 Hz, 1H), 6.84 (d, J=8 Hz, 1H), 6.91-6.96 (m, 1H), 7.17 (dd, J=8 and 2 Hz, 1H), 7.49 (d, J=8 Hz, 1H), 7.53-7.64 (m, 3H), 7.69 (dd, J=8 and 2 Hz, 1H), 8.25-8.30 (m, 1H), 8.57 (d, J=2 Hz, 1H); HRMS. Calc'd for M+H: 486.2076. Found: 486.2092.
Example 26
1-(2-phenyIethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyI]-3-pyridinyI]rnethyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-(2-phenylethyl)-4-butyl-1,3- dihydro-2-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2-phenylethyl)-4-butyl-1,3-dihydro-2-imidazol-2-one was prepared: NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 1.31 (m, J=7 Hz, 2H), 1.49 (m, J=7 Hz, 2H), 2.32 (td, J=7 and 1 Hz, 2H), 2.94 (t, J=7 Hz, 2H), 3.80 (t, J=7 Hz, 2H), 5.66 (t, J=1
Hz, 1H) , 7.15- 7.33 (m, 5H), 9.89 (br s, 1H); MS (FAB) m/e (rel intensity) 245 (100), 153 (10), 105 (50).
Step 2 : Preparation of 1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.85 (t, J=7 Hz, 3H), 1.22-1.47 (m, 4H), 2.24 (t, J=7 Hz, 2H), 2.99 (t, J=7 Hz, 2H), 3.90 (t, J=7 Hz, 2H), 4.93 (s, 2H), 5.80 (s, 1H), 7.16-7.47 (m, 5H), 7.48-7.59 (m, 4H), 8.05-8.12 (m, 1H), 8.47 (s, 1H); MS (FAB) m/e (rel intensity) 480 (100), 452 (20), 437 (5), 237 (18), 209 (8), 180 (81); HRMS. Calc'd for M+H: 480.2512. Found: 480.2561.
Example 27
1-(2-cyclopentylethyl)-4-buty!-1,3-dihydro-3-[[6-[2-(1H-tetrazoI-5- yl)phenyI]-3-pyridinyI]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1- (2-cyclopentylethyl) -4-butyl- 1 , 3-dihydro-2H-imidazol-2-one .
Following General Synthetic Schemes III and IV, 1-(2-cyclopentylethyl)-4-butyl-1,3-dihydro-2H-imidazol-2- one was prepared: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 1.00- 1.16 (m, 2H), 1.25-1.39 (m, 2H), 1.41-1.67 (m, 8H), 1.68-1.84 (m, 3H), 2.33 (t, J=8 Hz, 2H), 3.54 (t, J=8 Hz, 2H), 5.79-5.83 (m, 1H), 10.58 (br s, 1H); MS (FAB) m/e (rel intensity) 273 (100), 141 (8); HRMS. Calc'd for M+H:
237.1967. Found: 237.1898. Step 2 : Preparation of 1-(2-cyclopentylethyl)-4-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Scheme XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-cyclopentylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 1.06-1.20 (m, 2H), 1.23-1.87 (m, 13H) , 2.23 (t, J=7 Hz, 2H), 3.63 (t, J=7 Hz, 2H), 4.95 (s, 2H), 5.96 (s, 1H), 7.28
(d, J=8 Hz, 1H), 7.44-7.54 (m, 3H), 7.62 (dd, J=8 and 2 Hz, 1H), 7.97-8.04 (m, 1H) , 8.48 (d, J=2 Hz, 1H) ; MS (FAB) m/e
(rel intensity) 472 (100), 444 (27), 429 (5), 416 (3), 237 (19), 209 (65), 195 (19); HRMS. Calc'd for M+H: 472.2825. Found: 472.2881.
Example 28
1-[2-(cyclopenten-1-yl)ethyI]-4-butyI-1,3-dihydro-3-[[6-[2-(1H- tetrazoI-5-yI)phenyI]-3-pyridinyI]methyl]-2H-imidazoI-2-one
Step 1 : Preparation of 1- [2- (cyclopenten-1-yl ) ethyl ] -4-butyl-1 , 3-dihydro-2H-imidazol-2-one .
Following General Synthetic Schemes III and IV, 1-[2-(cyclopenten-1-yl)ethyl]-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 1.22-1.41 (m, 2H), 1.44-1.58 (m, 2H), 1.77-1.91 (m, 2H), 2.18-2.46 (m, 8H), 3.68 (t, J=8 Hz, 2H), 5.36-5.43 (m, 1H), 5.82-5.87 (m, 1H), 9.23 (br s, 1H); MS (FAB) m/e (rel intensity) 235 (90), 141 (100); HRMS. Calc'd for M+H:
235.1810. Found: 235.1804. Step 2 : Preparation of 1-[2-(cyclopenten-1-yl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-[2-(cyclopenten-1-yl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 1.21-1.39 (m, 2H), 1.39-1.53 (m, 2H), 1.86 (m, J=7 Hz, 2H), 2.28 (t, J=7 Hz, 6H), 2.45 (t, J=7 Hz, 2H), 3.76 (t, J=7 Hz, 2H), 4.95 (s, 2H), 5.41 (s, 1H), 5.96 (s, 1H), 7.45 (d, J=8 Hz, 1H), 7.49-7.63 (m, 3H), 7.76 (d, J=8 Hz, 1H), 8.12-8.20 (m, 1H), 8.55 (s, 1H); MS (FAB) m/e (rel
intensity) 470 (30), 442 (10); HRMS. Calc'd for M+H:
470.2668. Found: 470.2599.
Example 29
1-(2-adamantyI)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yI)phenyl]-3-pyridinyl]methyI]-2H-imidazoI-2-one
Step 1 : Preparation of 1- (2-adamantyl) -4-butyl-1, 3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2-adamentyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H) , 1.27-1.42 (m, 2H), 1.47-1.59 (m, 2H), 1.63 (br s, 1H), 1.67 (br s, 1H), 1.78 (br s, 2H), 1.84-2.02 (m, 8H), 2.37 (t, J=8 Hz, 2H), 2.42 (br s, 2H), 4.09 (s, 1H), 6.18-6.22 (m, 1H) , 9.53 (br s, 1H); MS (FAB) m/e (rel intensity) 275 (100), 141 (30), 135 (30); HRMS. Calc 'd for M+H: 275.2123. Found: 275.2065. Step 2 : Preparation of 1-(2-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-dimidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 1.32- 1.45 (m, 2H), 1.47-1.58 (m, 2H), 1.62-2.00 (m, 12H), 2.34 (t, J=8 Hz, 2H), 2.47 (br s, 2H), 4.15 (s, 1H), 4.96 (s, 2H), 6.35 (s, 1H), 7.51-7.58 (m, 2H), 7.61-7.68 (m, 2H), 7.93 (dd, J=8 and 2 Hz, 1H) , 8.13 (dd, J=6 and 4 Hz, 1H), 8.56 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 510 (100), 482 (10), 467 (5), 237 (10), 209 (10); HRMS. Calc'd for M+H: 510.2981. Found: 510.3038.
Example 30
1-(1-adamantyl)-4-butyI-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyI]-3-pyridinyl]methyl]-2H-imidazol-2-one
Preparation of 1-(1-adamantyl)-4-butyl-1,3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(1-adamentyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.92 (t, J=8 Hz, 3H), 1.29-1.43 (m, 2H), 1.47-1.59 (m, 2H), 1.72 (br s, 1H), 2.16 (br s, 3H), 2.21 (br s, 6H), 2.36 (t, J=8 Hz, 2H), 6.01 (br s, 1H), 9.43 (br s, 1H); MS (FAB) m/e (rel Intensity) 275 (100), 141 (6), 135 (83); HRMS. Calc'd for M+H: 275.2123. Found: 275.2057. Step 2 : Preparation of 1-(1-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(1-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 1.30- 1.42 (m, 2H), 1.42-1.54 (m, 2H), 1.64-1.71 (m, 6H), 2.07- 2.34 (m, 11H), 4.90 (s, 2H), 6.08 (s, 1H), 7.47-7.66 (m, 4H), 7.78 (dd, J=8 and 2 Hz, 1H), 8.20-8.25 (m, 1H), 8.57 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 510 (60), 482 (5), 467 (5), 237 (5); HRMS. Calc'd for M+H: 510.2981.
Found: 510.3033.
Example 31
1-phenyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyl]methyI]-2H-imidazol-2-one
Step 1 : Preparation of 1-phenyl-4-butyl-1 , 3-dihydro-2H- imidazol-2-one .
Following General Synthetic Schemes III and IV, 1-phenyl-4-butyl-1,3-dihydro-2H-imidazol-2-one was
prepared: NMR (CDCI3) δ 0.93 (t, J=7 Hz, 3H), 1.39 (m, J=7 Hz, 2H), 1.59 (m, J=7 Hz, 2H) , 2.42 (td, J=8 and 1 Hz, 2H), 6.26 (t, J=1 Hz, 1H), 7.21 (t, J=7 Hz, 1H), 7.41 (t, J=8
Hz, 2H), 7.57-7.62 (m, 2H) , 10.28 (br s, 1H); MS (FAB) m/e (rel intensity) 217 (100), 201 (2), 187 (3), 173 (11);
HRMS. Calc'd for M+H: 217.1341. Found: 217.1309. Step 2 : Preparation of 1-phenyl-4-butyl-1,3-dihydro-3- [[6-[2-(1H-tetrazol-5-yl)phenyl]-3-Pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-phenyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H) 1.40 (m, J=7 Hz, 2H), 1.55 (m, J=7 Hz, 2H), 2.39 (t, J=7 Hz, 2H), 5.05 (s, 2H), 6.38 (s, 1H), 7.20-7.26 (m, 1H), 7.34-7.56 (m, 6H), 7.59-7.66 (m, 2H), 7.85 (dd, J=8 and 2 Hz, 1H), 7.97-8.03 (m, 1H), 8.58 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 452 (51), 424 (23), 409 (7), 237 (13), 217 (13), 209 (100), 208 (67), 194 (38), 193 (38); HRMS. Calc'd for M+H: 452.2199. Found: 452.2248.
Example 32
1-(2-chlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yI)phenyl]-3-pyridinyI]methyl]-2H-imidazol-2-one
Step 1: Preparation of 1-(2-chlorophenyl)-4-butyl-1,3- dihvdro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2-chlorophenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 1.36 (m, J=7 Hz, 2H), 1.54 (m, J=7 Hz, 2H) , 2.37 (t, J=7 Hz, 2H), 6.06 (br s, 1H), 7.23-7.38 (m, 2H) , 7.41-7.53 (m, 2H) , 10.29 (br s, 1H); MS (FAB) m/e (rel intensity) 252 (36), 250 (100).
Step 2: Preparation of 1-(2-chlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-chlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 81-83° C; NMR (CDCI3) δ 0.90 (t, J=7 Hz, 3H), 1.39 (m, J=7 Hz, 2H), 1.54 (m, J=7 Hz, 2H), 2.37 (td, J=8 and 1 Hz, 2H), 5.03 (s, 2H), 6.19 (t, J=1 Hz, 1H), 7.31-7.37 (m, 2H), 7.46-7.63 (m, 6H), 7.88 (dd, J=8 and 2 Hz, 1H), 8.15-8.21 (m, 1H), 8.65 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 488 (15), 486 (37), 460 (5), 458 (8); HRMS. Calc'd for M+H: 486.1809. Found: 486.1781.
Example 33
1-(2-methylphenyl)-4-butyI-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yI)phenyI]-3-pyridinyI]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1- (2-methylphenyl) -4-butyl-1, 3 - dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2-methylphenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.92 (t, J=7 Hz, 3H), 1.37 (m, J=7 Hz, 2H), 1.55 (m, J=7 Hz, 2H), 2.28 (s, 3H), 2.39 (td, J=7 Hz, 2H), 5.96-5.99 (m, 1H), 7.21-7.31 (m, 4H), 9.88 (br s, 1H); MS (FAB) m/e (rel intensity) 231 (100), 201 (2), 175 (2), 155 (3), 127 (4), 106 (3); HRMS. Calc'd for M+H: 231.1497. Found: 231.1448. Step 2: Preparation of 1-(2-methylphenyl)-4-butyI-1,3-dihydro-3-[[6-[2-(4H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-methyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.89 (t, J=8 Hz, 3H), 1.31-1.45 (m, 2H), 1.46-1.59 (m, 2H), 2.26 (s, 3H), 2.37 (td, J=8 and 1 Hz, 2H), 5.05 (s, 2H), 6.10 (t, J=1 Hz, 1H), 7.22-7.31 (m, 4H), 7.37 (d, J=8 Hz, 1H), 7.48-7.59 (m, 3H), 7.81 (dd, J=8 and 2 Hz, 1H), 7.98-8.05 (m, 1H), 8.57 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 466 (64), 438 (23), 237 (25), 231 (33), 209 (100), 194 (37), 193 (32), 180 (83); HRMS. Calc'd for M+H: 466.2355. Found: 466.2397.
Example 34
1-(2-methoxyphenyl)-4-butyI-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyI]-2H-imidazol-2-one
Step 1 : Preparation of 1-(2-methoxyphenyl)-4-butyl-1,3- dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2-methoxyphenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 1.37 (m, J=7 Hz, 2H), 1.56 (m, J=7 Hz, 2H), 2.40 (td, J=8 and 1 Hz, 2H), 3.83 (s, 3H), 6.08-6.12 (m, 1H), 6.96-7.04 (m, 2H), 7.29 (td, J=8 and 2 Hz, 1H), 7.43 (dd, J=8 and 2 Hz, 1H), 9.94 (s, 1H); MS (FAB) m/e (rel intensity) 247 (100), 217 (3), 203 (7); HRMS. Calc'd for M+H: 247.1447. Found:
247.1470.
Step 2 : Preparation of 1-(2-methoxyphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one. Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-methoxyphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 1.40 (m, J=7 Hz, 2H) , 1.53 (m, J=7 Hz, 2H), 2.40 (t, J=7 Hz, 2H), 3.83 (s, 3H), 5.06 (s, 2H), 6.20 (s, 1H), 6.96-7.03 (m, 2H), 7.27-7.34 (m, 3H), 7.42 (dd, J=8 and 2 Hz, 1H), 7.53-7.65 (m, 4H), 8.09-8.17 (m, 2H), 8.66 (s, 1H); MS (FAB) m/e (rel intensity) 482 (67), 454 (20), 439 (5), 247 (40), 237 (22), 209 (100), 208 (66), 194 (38), 193 (31); HRMS. Calc'd for M+H: 482.2304. Found: 482.2324.
Example 35
1-(2-isopropyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1- (2-isopropyIphenyl) - 4-butyl - 1 , 3-dihydro-2H-imidazol-2-one .
Following General Synthetic Schemes III and IV, 1-(2-isopropyIphenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 1.21 (d, J=7 Hz, 6H), 1.30-1.44 (m, 2H), 1.48-1.60 (m, 2H), 2.38 (t, J=7 Hz, 2H), 3.05 (m, J=7 Hz, 1H), 5.93-5.96 (m, 1H), 7.17-7.42 (m, 4H), 10.65 (br s, 1H); MS (FAB) m/e (rel
intensity) 259 (100); HRMS. Calc'd for M+H: 259.1810.
Found: 259.1799. Step 2: Preparation of 1-(2-isopropyIphenyl)-4-butyl- 1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-isopropyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.89 (t, J=7 Hz, 3H), 1.21 (d, J=7 Hz, 6H), 1.37 (m, J=7 Hz, 2H), 1.52 (m, J=7 Hz, 2H), 2.36 (t, J=7 Hz, 2H), 2.98 (m, J=7 Hz, 1H), 5.07 (s, 2H), 6.07 (s, 1H), 7.09-7.25 (m, 2H), 7.30-7.43 (m, 3H), 7.46-7.55 (m, 3H) , 7.81 (dd, J=8 and 1 Hz, 1H), 7.92-7.99 (m, 1H), 8.53 (d, J=1 Hz, 1H); MS (FAB) m/e (rel intensity) 494 (75), 466 (26), 451 (4), 259 (14), 237 (37), 209 (100), 208 (61), 194 (37), 193 (32); HRMS. Calc'd for M+H: 494.2668. Found: 494.2651.
Example 36
1-(2,6-difluorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yI)phenyI]-3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-(2,6-difluorophenyl)-4-butyl- 1,3-dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2,6-difluorophenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.93 (t, J=7 Hz, 3H), 1.31-1.46 (m, 2H), 1.50-1.62 (m, 2H), 2.41 (td, J=8 and 1 Hz, 2H), 6.05 (t, J=1 Hz, 1H), 6.98-7.08 (m, 2H), 7.27-7.39 (m, 1H), 9.18 (br s, 1H).
Preparation of 1-(2,6-difluorophenyl)-4-butyl- 1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or Scheme XXIII, the imidazol-2-one from Step 1 was
converted to 1-(2,6-difluorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 164.5-165.5° C (dec); NMR (CDCI3) δ 0.90 (t, J=8 Hz, 3H), 1.32-1.46 (m, 2H), 1.48-1.60 (m, 2H) , 2.37 (td, J=8 and 1 Hz, 2H) 5.04 (s, 2H), 6.14 (t, J=1 Hz, 1H), 7.05 (t, J=8 Hz, 2H), 7.29-7.38 (m, 1H), 7.42 (d, J=8 Hz, 1H), 7.48-7.58 (m, 3H), 7.81 (dd, J=8 and 2 Hz, 1H) , 8.04-8.11 (m, 1H), 8.60 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 488 (83), 460 (26), 253 (10), 237 (25), 209 (100), 194 (37), 193 (35), 180 (80); HRMS. Calc'd for M+H: 488.2010. Found: 488.1951.
Example 37
1-(2,6-dichlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
Step 1 : Preparation of 1-(2,6-dichlorophenyl)-4-butyl- 1,3-dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2,6-dichlorophenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.93 (t, J=7 Hz, 3H), 1.32-1.46 (m, 2H), 1.51-1.62 (m, 2H) , 2.43 (td, J=8 and 1 Hz, 2H), 5.94 (t, J=1 Hz, 1H), 7.27-7.32 (m, 1H), 7.40-7.46 (m, 2H), 9.33 (br s, 1H).
Step 2 : Preparation of 1-(2,6-dichlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Scheme XII and XIV or Scheme XXIII, the imidazol-2-one from Step 1 was
converted to 1-(2,6-dichlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 212.0-212.5° C; NMR (CDCI3) δ 0.88 (t, J=8 Hz, 3H), 1.30-1.44 (m, 2H), 1.47-1.59 (m, 2H), 2.34 (td, J=8 and 1 Hz, 2H), 5.10 (s, 2H), 6.04 (t, J=1 Hz, 1H), 7.28-7.35 (m, 2H), 7.42-7.55 (m, 5H), 7.76 (dd, J=8 and 2 Hz, 1H), 7.97-8.04 (m, 1H) , 8.53 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 522 (48), 520 (85), 494 (8), 492 (12), 287 (4), 285 (8), 237 (51), 209 (93), 194 (35), 193 (31), 180 (95); HRMS. Calc'd for M+H: 520.1419. Found: 420.1443.
Example 38
1-(2,6-dimethylphenyI)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yI)phenyl]-3-pyridinyl]methyI]-2H-imidazoI-2-one
Step 1 : preparation of 1- (2, 6-dimethylphenyl) -4-butyl - 1,3-dihydro-2H-imidazol-2-one.
Following General Synthetic Schemes III and IV, 1-(2,6-dimethyIphenyl)-4-butyl-1,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDCI3) δ 0.91 (t, J=7 Hz, 3H), 1.29-1.32 (m, 2H), 1.49-1.61 (m, 2H), 2.18 (s, 6H), 2.41 (t, J=7 Hz, 2H), 5.83-5.86 (m, 1H), 7.07-7.21 (m, 3H), 9.66 (br s, 1H); MS (FAB) m/e (rel intensity) 245 (100), 215 (4), 118 (9); HRMS. Calc'd for M+H: 245.1654. Found: 245.1668.
Step 2 : Preparation of 1-(2,6-dimethyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
Following General Synthetic Schemes XII and XIV or Scheme XXIII, the imidazol-2-one from Step 1 was
converted to 1-(2,6-dimethyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.91 (t, J=8 Hz, 3H), 1.33-1.47 (m, 2H), 1.49-1.61 (m, 2H), 2.09 (s, 6H), 2.42 (td, J=8 and 1 Hz, 1H), 5.09 (s, 2H) , 6.04 (t, J=1 Hz, 1H), 7.06-7.11 (m, 2H), 7.14-7.21 (m, 1H), 7.52-7.61 (m, 2H), 7.62-7.69 (m, 2H), 7.96-8.07 (m, 2H), 8.57 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 480 (53), 452 (22), 245 (23), 237 (25), 209 (98), 194 (45), 193 (42), 180 (100); HRMS. Calc'd for M+H: 480.2512. Found: 480.2551.
Example 39
1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2- pyridinyl]methyl]-2H-imidazol-2-one
Following General Synthetic Schemes XII and XIII, 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one (prepared in Step 2A of Example 1) was converted to 1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDCI3) δ 0.85 (t, J=7 Hz, 3H), 0.88 (t, J=7 Hz, 3H), 1.11-1.35 (m, 4H), 1.42 (m, J=7 Hz, 2H), 1.57 (m, J= 7 Hz, 2H), 2.27 (t, J=7 Hz, 2H), 3.57 (t, J=7 Hz, 2H), 4.78 (s, 2H), 5.93 (s, 1H), 6.86 (d, J=8 Hz, 1H), 7.35 (dd, J=8 and 2 Hz, 1H), 7.42 (d, J=8 Hz, 1H), 7.52-7.56 (m, 1H), 7.58- 7.62 (m, 1H), 7.89 (d, J=8 Hz, 1H), 8.27 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 425 (66), 404 (15), 389 (15), 237 (6), 208 (82), 193 (43), 180 (100); HRMS. Calc'd for
M+L: 438.2594. Found: 438.2645. Anal. Calc'd for C24H29N7O:
C, 66.80; H, 6.77; N, 22.72. Found: C, 67.15; H, 6.83; N, 22.94. Example 40
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazoI-2-one
Following General Synthetic Schemes XXVIII, XXIV, and XX, 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one (prepared in Step 2A of Example 1) was converted to 1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 178.0-179.5° C; NMR (CDCI3) δ 0.85 (t, J=7 Hz, 3H), 0.88 (t, J=7 Hz, 3H), 1.23-1.49 (m, 6H), 1.50-1.63 (m, 2H), 2.20 (t, J=7 Hz, 2H), 3.50 (t, J=7 Hz, 2H), 4.70 (s, 2H), 5.94 (s, 1H) , 7.02 (d, J=8 Hz, 2H), 7.22 (d, J=8 Hz, 2H), 7.56 (dd, J=5 and 3 Hz, 1H) , 8.31 (d, J=5 Hz, 1H), 8.77 (d, J=3 Hz, 1H) ; MS (FAB) m/e (rel intensity) 432 (21), 389 (4), 237 (8), 209 (28), 208 (100), 194 (20), 180 (14), 153 (7); HRMS. Calc'd for M+H: 432.2512. Found:
432.2558. Example 41
1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazoI-5-yI)-3- pyridinyl]phenyI]methyI]-2H-imidazol-2-one
Following General Synthetic Schemes XXVIII, XXV, and XX, 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one (prepared in Step 2A of Example 1) was converted to 1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 128-130° C; NMR (CDCI3) δ 0.86 (t, J=7 Hz, 3H), 0.89 (t, J=7 Hz, 3H), 1.21-1.36 (m, 4H), 1.36-1.49 (m, 2H), 2.21 (t, J=7 Hz, 2H), 4.74 (s, 2H), 5.96 (s, 1H), 7.04 (d, J=8 Hz, 2H), 7.11 (d, J=8 Hz, 2H), 7.90 (d, J=5 Hz, 1H), 8.64 (s, 1H), 8.66 (d, J=5 Hz, 1H); MS (FAB) m/e (rel Intensity) 432 (20), 389 (10), 208 (100), 197 (30), 193 (30); HRMS. Calc'd for M+H: 432.2512. Found: 432.2508.
Example 42
1,4-dibutyI-1,3-dihydro-3-[[4-[3-(1H-tetrazoI-5-yl)-4- pyridinyl]phenyI]methyI]-2H-imidazol-2-one
Following General Synthetic Schemes XXVIII, XXVI, and XX, 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one (prepared in Step 2A of Example 1) was converted to 1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 176-178° C (dec); NMR (CDCI3) δ 0.86 (t, J=7 Hz, 3H), 0.90 (t, J=7 Hz, 3H), 1.22-1.36 (m, 4H), 1.37-1.49 (m, 2H), 1.53-1.66 (m, 2H), 2.22 (t, J=8Hz, 2H), 3.57 (t,
J=8Hz, 2H), 4.72 (s, 2H), 5.96 (s, 1H), 7.01 (d, J=9Hz, 2H), 7.09 (d, J=9Hz, 2H), 7.43 (d, J=5Hz, 1H), 8.71 (d, J=5Hz, 1H), 8.87 (s, 1H); MS (FAB) m/e (rel intensity) 432 (22), 404 (3), 389 (5), 237 (22), 208 (100), 193 (34), 180 (75), 167 (18), 153 (22), 141 (10), 128 (6), 111 (12);
HRMS. Calc'd. for M+H: 432.2512. Found: 432.2512. Example 43
1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3- pyridinyl]phenyl]methyl]-2H-imidazoI-2-one
Following General Synthetic Schemes XXVIII, XXVII, and XX, 1,4-dibutyl-1,3-dihydro-2H-imidazol-2-one (prepared in Step 2A of Example 1) was converted to 1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one as a colorless solid: mp 178.0-179.5° C; NMR (CDCI3) δ 0.88 (t, J=7 Hz, 3H), 0.93 (t, J=7 Hz, 3H), 1.25-1.54 (m, 6H), 1.59-1.72 (m, 2H), 2.28 (t, J=7 Hz, 2H), 3.64 (t, J=7 Hz, 2H) , 4.85 (s, 2H), 5.97 (s, 1H), 7.05 (d, J=9 Hz, 2H), 7.10 (d, J=9 Hz, 2H), 7.55 (dd, J=5 and 3 Hz, 1H), 7.80 (d, J=5 Hz, 1H), 8.68 (d, J=3 Hz, 1H); MS (FAB) m/e (rel intensity) 432 (27), 389 (5), 237 (4), 209 (29), 208 (100), 194 (21), 180 (45), 153 (10); HRMS. Calc'd for M+H: 432.2512. Found:
432.2563. BIOLOGICAL EVALUATION
Assay A: Angiotensin II Binding Activity Compounds of the invention were tested for ability to bind to the smooth muscle angiotensin II receptor using a rat uterine membrane preparation.
Angiotensin II (All) was purchased from Peninsula Labs. 125I-angiotensin II (specific activity of 2200 Ci/mmol) was purchased from Du Pont-New England Nuclear. Other chemicals were obtained from Sigma Chemical Co. This assay was carried out according to the method of Douglas et al
[Endocrinology, 106, 120-124 (1980)]. Rat uterine membranes were prepared from fresh tissue. Ml procedures were carried out at 4°C. Uteri were stripped of fat and
homogenized in phosphate-buffered saline at pH 7.4
containing 5 mM EDTA. The homogenate was centrifuged at 1500 × g for 20 min., and the supernatant was recentrifuged at 100,000 × g for 60 min. The pellet was resuspended in buffer consisting of 2 mM EDTA and 50 mM Tris-HCl (pH 7.5) to a final protein concentration of 4 mg/ml. Assay tubes were charged with 0.25 ml of a solution containing 5 mM MgCl2, 2 mM EDTA, 0.5% bovine serum albumin, 50 mM Tris-HCl, pH 7.5 and 125I-AII (approximately 105 cpm) in the absence or in the presence of unlabelled ligand. The reaction was initiated by the addition of membrane protein and the mixture was incubated at 25°C for 60 min. The incubation was terminated with ice-cold 50 mM Tris-HCl (pH 7.5) and the mixture was filtered to separate membrane-bound labelled peptide from the free ligand. The incubation tube and filter were washed with ice-cold buffer. Filters were assayed for radioactivity in a Micromedic gamma counter. Nonspecific binding was defined as binding in the presence of 10 μM of unlabelled AII. Specific binding was calculated as total binding minus nonspecific binding. The receptor binding affinity of an AII antagonist compound was indicated by the concentration (IC50) of the tested AII antagonist which gives 50% displacement of the total specifically bound 125 I-AII from the high affinity AII receptor. Binding data were analyzed by a nonlinear least- squares curve fitting program. Results are reported in Table I .
Assay B: In Vitro Vascular Smooth Muscle-Response for AII
The compounds of the invention were tested for antagonist activity in rabbit aortic rings . Male New
Zealand white rabbits (2-2.5 kg) were sacrificed using an overdose of pentobarbital and exsanguinated via the carotid arteries . The thoracic aorta was removed, cleaned of adherent fat and connective tissue and then cut into 3-mm ring segments . The endothelium was removed from the rings by gently sliding a rolled-up piece of filter paper into the vessel lumen. The rings were then mounted in a water- jacketed tissue bath, maintained at 37°C, between moveable and fixed ends of a stainless steel wire with the moveable end attached to an FT03 Grass transducer coupled to a Model 7D Grass Polygraph for recording isometric force responses . The bath was filled with 20 ml of oxygenated (95% oxygen/5% carbon dioxide) Krebs solution of the following composition (mM) : 130 NaCl, 15 NaHCO 3, 15 KCl, 1 .2 NaH2PO4 , 1 .2 MgSO4 , 2. 5 CaCl2 , and 11 .4 glucose . The preparations were
equilibrated for one hour before approximately one gram of passive tension was placed on the rings . Angiotensin II concentration-response curves were then recorded (3 X 10 -10 to 1 X 10 -5 M) . Each concentration of AII was allowed to elicit its maximal contraction, and then AII was washed out repeatedly for 30 minutes before rechallenging with a higher concentration of AII. Aorta rings were exposed to the test antagonist at 10-5 M for 5 minutes before
challenging with AII. Adjacent segments of the same aorta ring were used for all concentration-response curves in the presence or absence of the test antagonist . The
effectiveness of the test compound was expressed in terms of pA2 values and were calculated according to H. O. Schild [Br. J. Pharmacol. Chemother., 2,189-206 (1947)]. The pA2 value is the concentration of the antagonist which
increases the EC50 value for AII by a factor of two. Each test antagonist was evaluated in aorta rings from two rabbits. Results are reported in Table I.
Assay C: In Vivo Intragastric Pressor Assay Response for All Antagonists
Male Sprague-Dawley rats weighing 225-300 grams were anesthetized with methohexital (30 mg/kg, i.p.) and catheters were implanted into the femoral artery and vein. The catheters were tunneled subcutaneously to exit
dorsally, posterior to the head and between the scapulae. The catheters were filled with heparin (1000 units/ml of saline). The rats were returned to their cage and allowed regular rat chow and water ad libitum. After full recovery from surgery (3-4 days), rats were placed in Lucite holders and the arterial line was connected to a pressure
transducer. Arterial pressure was recorded on a Gould polygraph (mmHg). Angiotensin II was administered as a 30 ng/kg bolus via the venous catheter delivered in a 50 μl volume with a 0.2 ml saline flush. The pressor response in mm Hg was measured by the difference from pre-injection arterial pressure to the maximum pressure achieved. The AII injection was repeated every 10 minutes until three consecutive injections yielded responses within 4 mmHg of each other. These three responses were then averaged and represented the control response to AII. The test compound was suspended in 0.5% methylcellulose in water and was administered by gavage. The volume administered was 2 ml/kg body weight. The standard dose was 3 mg/kg.
Angiotensin II bolus injections were given at 30, 45, 60, 75, 120, 150, and 180 minutes after gavage. The pressor response to AII was measured at each time point. The rats were then returned to their cage for future testing. A minimum of 3 days was allowed between tests. Percent inhibition was calculated for each time point following gavage by the following formula: [ (Control Response - Response at time point)/Control Response] X 100. Results are shown in Table I.
TABLE I
In Vitro and In Vivo Aneiotensin II
Activity of Compounds of the Invention
Test 1 Assay A 2Assay B 3Assa ty C
Compound IC50 (nM) pA2 Dose : 3 mg/kg (i.g.)
Example # Inhibition (% ) Duration (min.)
1 6.5 8.82/8.53 50 > 180
2 38 8.13/7.40 25 180
3 770 7.46/6.95 NA
4 140 7.72/7.09 NA
5 29 8.64/8.23 NA
6 10 7.87/7.89 10 180
7 81 7.75/7.76 10 180
8 140 NA NA
9 11 9.27/8.87 10 180
10 47 7.64/7.35 NA
1 1 34 8.44/8.03 NA
12 31 7.68/8.26 NA
13 14 8.03/8.60 NA
14 7.6 8.76/8.64 35 > 180
15 10 8.79/8.85 60 > 180
16 20 8.42/8.77 45 > 180
17 17 8.78/8.63 10 180
18 12 8.79/8.64 65 > 180
19 9.2 8.43/8.36 50 > 180
20 16 9.17/8.86 75 > 180
21 20 9.14/9.15 40 > 180
22 5.4 8.75/8.89 30 > 180
23 99 9.04/8.60 NA
24 22 9.19/8.69 50 > 180
25 5.0 9.41/9.16 25 > 180
26 3.6 8.36/8.44 15 180
27 18 8.74/8.67 35 > 180
28 23 8.85/8.25 15 180
29 51 NA NA
30 65 NA NA
31 45 NA NA
32 5.4 8.80/9.04 50 > 180 TABLE I (CONTINUED)
In Vitro and In Vivo Angiotensin II
Activity of Compounds of the Invention
Test 1 Assay A 2Assay B 3Assay C
Compound IC50 (nM) pA2 Dose: 3mg/kg (i.g.)
Example # Inhibition (%) Duration (min.)
33 9.4 NA 65 > 180
34 9.0 NA NA
35 14 NA NA
36 7.0 NA 75 120
37 4.8 NA 25 > 180
38 5.0 NA NA
39 14 7.45/7.87 20 > 180
40 91 NA NA
41 160 NA NA
42 93 NA NA
43 89 7.55/7.67 NA
1 Assay A: Angiotensin II Binding Activity
2Assay B: In Vitro Vascular Smooth Muscle Response
3 Assay C: In Vivo Pressor Response (all test compounds
administered intragastrically at 3 mg/kg).
*NA = Not Assayed
Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula I in association with one or more non- toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as
"carrier" materials) and, if desired, other active
ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The compounds and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical
composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules.
These may with advantage contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.1 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate.
The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose is from about 0.1 to 100 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 30 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 100 mg per kilogram of body weight per day. A more
preferred dosage will be a range from about 1 mg to about 100 mg per kilogram of body weight. Most preferred is a dosage in a range from about 1 to about 50 mg per kilogram of body weight per day. A suitable dose can be
administered, in multiple sub-doses per day. These sub- doses may be administered in unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 100 mg of active compound per unit dosage form. A more
preferred dosage will contain from about 2 mg to about 50 mg of active compound per unit dosage form. Most preferred is a dosage form containing from about 3 mg to about 25 mg of active compound per unit dose.
The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of administration, and the particular compound employed, and thus may vary widely.
For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more
adjuvants appropriate to the indicated route of
administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids,
gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral
administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

Claims

What Is Claimed Is :
1 . A compound of Formula I
wherein A is selected from
wherein m is a number selected from one to four,
inclusive; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, thienylalkyl,
phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, cycloalkylcarbonyl,
cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl,
alkylthiocarbonyl, alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl,
alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,
aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R12 and R13 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R12 and R13 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; wherein each of R0 and R2 through R11 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, alkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R14 and R15 taken together, R16 and R17 taken together, R18 and R19 taken together, R21 and R22 taken together and R23 and R24 taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R14 and R15 taken together, R16 and R17 taken together, R21 and R22 taken together and R23 and R24 taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic
heterocyclic group may further contain one or more
additional nitrogen atoms; and wherein each of R0 and R3 through R11 may be further independently selected from hydroxy and acidic moieties of the formula -YnA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;
wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR32 and
wherein D is selected from oxygen atom and sulfur atom and R32 is selected from hydrido, alkyl, cycloalkyl,
cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl, and wherein each of R27, R28, R29, R30, R31, R33 and R34 is further
independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R35, R36, R37, R38, R39 and R40 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R28 and R29 taken together and each of R30 and R31 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein each of R28 and R29 taken together and each of R33 and R34 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
2. Compound of Claim 1 wherein m is one;
wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
alkylthiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto,
alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,
aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,
cycloheteroalkyl, cycloheteroalkylalkyl and
cycloheteroalkylcarbonylalkyl wherein each of said
heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,
cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,
alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, arylthio, arylthiocarbonyl,
arylcarbonylthio, arylthiocarbonyloxy,
arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula -YnA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,
cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR32 and
wherein D is selected from oxygen atom and sulfur atom, and R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,
alkoxycarbonyl, carboxyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
3. Compound of Claim 2 wherein m is one;
wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl,
alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl- containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R36, R37, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, hajoalkylcarbonyl,
cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R35, R36, R37 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R36 and R37 may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent position,s selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R0 through R26 and R35 through R41, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl,
hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein R27 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR32 and
wherein D is selected from oxygen atom and sulfur atom; wherein R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,
alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
4. Compound of Claim 3 wherein m is one;
wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl,
cycloalkenyl, alkynyl, mercaptocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; . wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,
cycloalkylalkyl, aryl and aralkyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of
carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which
heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
5. Compound of Claim 4 wherein m is one;
wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,
carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl- containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through .two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially
unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A and independently may be substituted at any
substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,
alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
6. Compound of Claim 5 wherein m is one;
wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkenyl and alkynyl; where each of R0 and R2 is independently selected from hydrido, alkyl, aminoalkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,
alkylcarbonyl, alkylcarbonyloxy, mercaptoalkyl,
mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio,
cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties consisting of CO2H, CO2CH3, SH, CH2SH, C2H4SH, PO3H2, NHSO2CF3,
NHSO2C6F5, SO3H, CONHNH2, CONHNHSO2CF3, CONHOCH3,
CONHOC2H5, CONHCF3, OH, CH2OH, C2H4OH, OPO3H2, OSO3H ,
wherein each of R42, R43 and R44 is independently selected from H, Cl, CN, NO2, CF3, C2F5, C3F7, CHF2, CH2F, CO2CH3, CO2C2H5, SO2CH3 SO2CF3 and SO2C6F5; wherein Z is selected from O, S, NR45 and CH2; wherein R45 is selected from hydrido, CH3 and CH2C6H5. and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R3 through R11 so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from
and the esters, amides and salts of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
7. Compound of Claim 6 wherein m is one;
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido,
C4H9(n), CH3CH2CH=CH, C3H7(n), SC3H7,
C2H5. C5Hn(n), C6Hι3(n), SC4H9,
CH3CH=CH, CH3CH2CH2CH=CH-, amino, aminomethyl, aminoethyl, aminopropyl, CH2OH, CH2OCOCH3, CH2CI, CH2OCH3, CH2θCH(CH3) 2, CHO,
CH2CO2H, CH(CH3)CO2H, NO2, Cl,
- -CO2CH3, -CONH2, -CONHCH 3, CON (CH3) 2 -
-CH2-NHCO2C2H5, -CH2NHCO2CH3, -CH2NHCO2C3H7,
-CH2NHCO2CH2(CH 3) 2, -CH2NHCO 2C4H9, CH2NHCO2-adamantyl,
-CH 2NHCO2- (1-napthyl) , -CH2NHCONHCH3, -CH2NHCONHC 2H5,
-CH 2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2,
-CH2NHCONH ( 1-naρthyl) , -CH2NHCONH (1-adamantyl ) ,
- -CH2CH2CH2CO2H,
-CH2CH2F, -CH2OCONHCH 3, -CH2OCSNHCH 3, -CH2NHCSOC 3H7,
-CH2CH2CH2F, -CH2ONO2, -CH2SH,
Cl, NO2, CF3, CH2OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, cyclohexyl,
cyclohexylmethyl, carboxyl, formyl, 1-oxoethyl,
1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl. 1,1-difluoro-2-phenylethyl, monofluoromethyl,
1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,
1,1 -difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,
1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, difluoromethyl, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl-, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2 SO3H, CONHNH2, CONHNHSO2CF3, OH, wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
8. Compound of Claim 7 wherein m is one;
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1- oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n- pentyl, neopentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1- oxopentyl 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio, butylthio, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienyIpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
9. Compound of Claim 8 wherein m is one;
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl,
1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl. 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,
neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R5 and R9 is an acidic group selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3,
OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
10. Compound of Claim 9 wherein m is one;
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio. butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; with the proviso that at least one of R5 and R9 must be selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
11. Compound of Claim 10 wherein m is one;
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl
cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R5 and R9 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
12. Compound of Claim 11 selected from a family of compounds of Formula II
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl. 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
13. Compound of Claim 12 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
14. Compound of Claim 13 selected from
compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]- 2-pyridinyl] methyl] -2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] methyl] -2H-imidazol-2-one;
1-isopentyl-4-butyl-l , 3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1,4-dibutyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one.
15. Compound of Claim 11 selected from a family of compounds of Formula III
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
16. Compound of Claim 15 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is
selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,
neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl,
cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl,
fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
17. Compound of Claim 16 selected from
compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-butyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-isopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-cyclohexyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-cyclopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-(2-cyclopropylethyl)-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-neopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(3,3-dimethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclopropylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-cyclopentylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-[2-(2-thienyl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclopentylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-[2-(cyclopenten-1-yl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(1-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-chlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-methylphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-methoxyphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-isopropyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2,6-difluorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-iιnidazol-2-one;
1-(2,6-dichlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; and
1-(2,6-dimethyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one.
18. Compound of Claim 11 selected from a family of compounds of Formula IV
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
19. Compound of Claim 18 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropyIphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
20. Compound of Claim 19 selected from
compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-{3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) -2-pyridinyl]phenyl] methyl] -2H-imidazol-2-one; 1, 4-dibutyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5 -yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
21. Compound of Claim 11 selected from a family of compounds of Formula V
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl. phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
22. Compound of Claim 21 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
23. Compound of Claim 22 selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-1[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one; 1-propyl-4-butyl-5-chloro-1, 3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
24. Compound of Claim 11 selected from a family of compounds of Formula VI
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl. cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamaatylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
25. Compound of Claim 24 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thieny lpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
26. Compound of Claim 25 selected from
compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-prcrpyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1- (2-phenylethyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) -4-pyridinyl]phenyl] methyl ] -2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-pentyl-4-butyl-5-methyl-1,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and 1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
27. Compound of Claim 11 selected from a family of compounds of Formula VII
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
28. Compound of Claim 27 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, secbutyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclqbutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
29. Compound of Claim 28 selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1, 4-dibutyl-5-chloro-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5 -yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[2- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
30. Compound of Claim 17 which is 1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof.
31. Compound of Claim 17 which is
1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
or a pharmaceutically-acceptable salt thereof.
32. A pharmaceutical composition comprising a therapeutically-effective amount of an angiotensin II antagonist compound and a pharmaceutically-acceptable carrier or diluent, said antagonist compound selected from a family of compounds of Formula I
wherein A is selected from
wherein m is a number selected from one to four,
inclusive; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, thienylalkyl,
phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, cycloalkylcarbonyl,
cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl,
alkylthiocarbonyl, alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl,
alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,
aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R12 and R13 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R12 and R13 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; wherein each of R0 and R2 through R11 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, alkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
—
wherein X is oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R14 and R15 taken together, R16 and R17 taken together, R18 and R19 taken together, R21 and R22 taken together and R23 and R24 taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R14 and R15 taken together, R16 and R17 taken together, R21 and R22 taken together and R23 and R24 taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic
heterocyclic group may further contain one or more
additional nitrogen atoms; and wherein each of R0 and R3 through R11 may be further independently selected from hydroxy and acidic moieties of the formula -YnA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;
wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR32 and
wherein D is selected from oxygen atom and sulfur atom and R32 is selected from hydrido, alkyl, cycloalkyl,
cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl, and wherein each of R27, R28, R29, R30, R31, R33 and R34 is further
independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R35, R36, R37, R38, R39 and R40 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R28 and R29 taken together and each of R30 and R31 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein each of R28 and R29 taken together and each of R33 and R34 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
33. The composition of Claim 32 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylthiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto,
alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,
aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,
cycloheteroalkyl, cycloheteroalkylalkyl and
cycloheteroalkylcarbonylalkyl wherein each of said
heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,
cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,
alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, arylthio, arylthiocarbonyl,
arylcarbonylthio, arylthiocarbonyloxy,
arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula -YnA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,
cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR32 and
wherein D is selected from oxygen atom and sulfur atom, and R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,
alkoxycarbonyl, carboxyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
34. The composition of Claim 33 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl,
alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R36, R37, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,
cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R35, R36, R37 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R36 and R37 may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R0 through R26 and R35 through R41, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl,
hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein R27 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR32 and
wherein D is selected from oxygen atom and sulfur atom; wherein R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,
alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
35. The composition of Claim 34 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkenyl, cycloalkenyl, alkynyl,
mercaptocarbonyl, alkylsulfonyl. aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,
cycloalkylalkyl, aryl and aralkyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of
carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which
heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
36. The composition of Claim 35 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl,
aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,
carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula -YnA wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially
unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A and independently may be substituted at any
substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,
alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
37. The composition of Claim 36 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl,
cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl and alkynyl; where each of R0 and R2 is independently selected from hydrido, alkyl, aminoalkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,
alkylcarbonyl, alkylcarbonyloxy, mercaptoalkyl,
mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties consisting of CO2H, CO2CH3, SH, CH2SH, C2H4SH, PO 3H2, NHSO2CF3 ,
NHSO 2C6F5, SO3H, CONHNH2, CONHNHSO2CF3 , CONHOCH 3 ,
CONHOC2H5, CONHCF 3 , OH, CH2OH, C2H4OH, OPO 3H2 , OSO 3H ,
wherein each of R42, R43 and R44 is independently selected from H, Cl, CN, NO2, CF3; C2F5, C3F7, CHF2, CH2F, CO2CH3, CO2C2H5, SO2CH3 SO2CF3 and SO2C6F5; wherein Z is selected from O, S, NR45 and CH2- wherein R45 is selected from hydrido, CH3 and CH2C6H5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R3 through R11 so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from
and the esters, amides and salts of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
38. The composition of Claim 37 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido,
C4H9(n), CH3CH2CH=CH, C3H7(n), SC3H7,
C2H5, C5H11(n), C6H13(n), SC4H9,
CH3CH=CH, CH3CH2CH2CH=CH-, amino, aminomethyl, aminoethyl, aminopropyl, CH2OH, CH2OCOCH3, CH2CI, CH2OCH3, CH2OCH(CH3)2, CHO,
CH2CO2H, CH(CH3)CO2H, NO2, Cl,
- -CO2CH3, -CONH2, -CONHCH 3, CON (CH3) 2,
-CH2-NHCO2C2H5, -CH2NHCO 2CH3, -CH2NHCO2C3H7,
-CH2NHCO2CH2(CH3) 2 , -CH2NHCO2C4H9, CH2NHCO2-adamantyl,
-CH2NHCO2- (1-napthyl) , -CH2NHCONHCH3, -CH2NHCONHC2H5,
-CH2NHCONHC3H7, -CH2NHCONHC4H9, -CH2NHCONHCH(CH3)2, -CH2NHCONH (1-napthyl) , -CH2NHCONH (1-adamantyl) , -CH2CH2CH2CO2H,
-CH2CH2F, -CH2OCONHCH 3, -CH2OCSNHCH 3, -CH2NHCSOC 3H7,
-CH2CH2CH2F, -CH2ONO2, -CH2SH,
Cl, NO2, CF3, CH2OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, cyclohexyl, cyclohexylmethyl, carboxyl, formyl, 1-oxoethyl,
1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,
1,1-difluoro-2-phenylethyl, monofluoromethyl,
1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,
1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,
1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, difluoromethyl, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
39. The composition of Claim 38 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl. thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n- pentyl, neopentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,
1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio, butylthio, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3,
OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl. phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO 3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
40. The composition of Claim 39 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl,
1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl,
1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec¬butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,
neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R5 and R9 is an acidic group selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3,
OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
41. The composition of Claim 40 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; with the proviso that at least one of R5 and R9 must be selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
42. The composition of Claim 41 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio, butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7,
R8, R10 and R11 is hydrido; wherein one bf R5 and R9 is hydrido and the other of R5 and R9 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
43. The composition of Claim 42 wherein said antagonist compound is selected from a family of compounds of Formula II
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
44. The composition of Claim 43 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof .
45. The composition of Claim 44 wherein said antagonist compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]- 2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one.
46. The composition of Claim 42 wherein said antagonist compound is selected from a family of compounds of Formula III
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl. adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
47. The composition of Claim 46 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl,
cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl,
fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
48. The composition of Claim 47 wherein said antagonist compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridiriyl]methyl]-2H-imidazol-2-one;
1-propyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-isopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-cyclohexyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-butyl-4-cyclopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-(2-cyclopropylethyl)-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-im-dazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyllmethyl]-2H-imidazol-2-one;
l-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
l-neopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(3,3-dimethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclopropylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclopentylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-[2-(2-thienyl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1- (2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-(2-cyclopentylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-[2-(cyclopenten-1-yl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(1-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-chlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-methyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-methoxyphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-isopropyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyllmethyl]-2H-imidazol-2-one;
1- (2, 6-difluorophenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (1H-tetrazol-5- yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one;
1- (2, 6-dichlorophenyl) -4-butyl-l, 3-dihydro-3- [ [6-[2- (1H-tetrazol-5- yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one; and
1- (2, 6-dimethyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one .
49. The composition of Claim 42 wherein said antagonist compound is selected from a family of compounds of Formula IV
wherein R1 is selected from methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyc-iopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R3 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
50. The composition of Claim 49 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
51. The composition of Claim 50 wherein said antagonist compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3- [4- [3- (1H- tetrazol-5-yl) -2-pyridiny1]phenyl] -2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3- [4- [3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3- [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl] -2H-imidazol-2-one;
1- (2-cyclohexylethyl) -4-butyl-5-methyl-1,3-dihydro-3- [4- [3- (1H-tetrazol-5-yl) -2-pyridinyl]phenyl] -2H-imidazol-2-one;
1- (2-phenylethyl) -4-butyl-5-methyl-1,3-dihydro-3- [4- [3- (1H-tetrazol-5-yl) -2-pyridinyl]phenyl] -2H-imidazol-2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3- [4- [3- (1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[4-[3-(1H-tetrazol- 5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]-2H-imidazol-2-one.
52. The composition of Claim 42 wherein said antagonist compound is selected from a family of compounds of Formula V
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
53. The composition of Claim 52 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl. cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and ;
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
54. The composition of Claim 53 wherein said antagonist compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-propyl-4-butyl-5-methyl-1, 3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1, 3-dihydro-3- [ [ 4- [4- (1H-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1, 3-dihydro-3- [ [4- [4 - (1H-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
55. The composition of Claim 42 wherein said antagonist compound is selected from a family of compounds of Formula VI
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl. methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
56. The composition of Claim 55 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl. cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
57. The composition of Claim 56 wherein said antagonist compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of 1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
58. The composition of Claim 42 wherein said antagonist compound is selected from a family of compounds of Formula VII
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R3 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
59. The composition of Claim 58 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
60. The composition of Claim 59 wherein said antagonist compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1- (2-cyclohexylethyl) -4-butyl-1, 3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) -3-pyridinylI phenyll methyl] -2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinylIphenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-5-chloro-1, 3-dihydro-3- [ [4- [-2 (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
61. The composition of Claim 48 wherein said antagonist compound is 1,4-dibutyl-1,3-dihydro-3-[[6-[2- (1H-tetrazol-5-yl)phenyl]-3-pyridinyllmethyl]-2H-imidazol- 2-one or a pharmaceutically-acceptable sa'lt thereof.
62. The composition "of Claim 48 wherein said antagonist compound is
1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
or a pharmaceutically-acceptable salt thereof.
63. A therapeutic method for treating a
circulatory disorder, said method comprising administering to a subject susceptible to or afflicted with such disorder a therapeutically-effective amount of an active compound of Formula I :
wherein A is selected from
wherein m is a number selected from one to four, inclusive; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, thienylalkyl,
phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, cycloalkylcarbonyl,
cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl,
alkylthiocarbonyl, alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl,
alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,
aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R12 and R13 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R12 and R13 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; wherein each of R0 and R2 through R11 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, alkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl. arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R14 and R15 taken together, R16 and R17 taken together, R18 and R19 taken together, R21 and R22 taken together and R23 and R24 taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R14 and R15 taken together, R16 and R17 taken together, R21 and R22 taken together and R23 and R24 taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic
heterocyclic group may further contain one or more
additional nitrogen atoms; and wherein each of R0 and R3 through R11 may be further independently selected from hydroxy and acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;
wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R13 through R26, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl,
aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aralkylsulfinyl,
aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR32 and
wherein D is selected from oxygen atom and sulfur atom and R32 is selected from hydrido, alkyl, cycloalkyl,
cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl, and wherein each of R27, R28, R29, R30, R31, R33 and R34 is further
independently selected from amino and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R35, R36, R37, R38, R39 and R40 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R28 and R29 taken together and each of R30 and R31 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein each of R28 and R29 taken together and each of R33 and R34 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more additional nitrogen atoms; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
64. The method of Claim 63 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
alkylthiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula
wherein X is oxygen atom or sulfur atom;
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,
arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto,
alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,
aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,
cycloheteroalkyl, cycloheteroalkylalkyl and
cycloheteroalkylcarbonylalkyl wherein each of said
heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula ti
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,
cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,
alkylthiocarbonyloxy, alkylthiocarbonylthio,
alkylthiothiocarbonyl, arylthio, arylthiocarbonyl,
arylcarbonylthio, arylthiocarbonyloxy,
arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,
aralkylthiocarbonylthio, aralkylthiocarbonyl,
aralkylthiocarbonylthio, mercapto, alkylsulfonyl,
aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula wherein X is oxygen atom or sulfur atom;
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,
cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R0 through R26, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula wherein X is oxygen atom or sulfur atom; wherein each of R27 through R31 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR32 and
wherein D is selected from oxygen atom and sulfur atom, and R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,
alkoxycarbonyl, carboxyl, haloalkylsulfinyl,
haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
65. The method of Claim 64 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl,
alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,
aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,
arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl- containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom or sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula
wherein each of R14, R15, R16, R17, R18 and R19 is
independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R33, R36, R37, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,
cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R33, R36, R37 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially
unsaturated; wherein R413 and R4i taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R36 and R37 may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R0 through R26 and R35 through R41, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl,
hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbanyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and
alkylthiocarbonyl, and amino and amido radicals of the formula wherein X is selected from oxygen atom and sulfur atom; wherein R27 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR32 and
wherein D is selected from oxygen atom and sulfur atom; wherein R32 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R27, R28, R29, R30, R31, R33 and R34 is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,
alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl,
haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
66. The method of Claim 65 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl,
cycloalkenyl, alkynyl, mercaptocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro,
carboxyl, carboxyalkyl, alkylcarbonyloxy,
alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,
aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,
mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkyIsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R2 through R11 may be further independently selected from amino and amido radicals of the formula wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
monoalkylamino, dialkylamino, hydroxyalkyl,
cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from
wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,
cycloalkylalkyl, aryl and aralkyl; wherein each of R35 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R40 and R41 taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially
unsaturated; wherein R40 and R41 taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of
carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which
heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
67. The method of Claim 66 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aroyl, alkoxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aralkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amido radicals of the formula
wherein each of R12 and R13 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R0 and R2 is independently selected from hydrido, alkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,
cycloalkylcarbonyl, alkoxy, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,
carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,
cycloalkylalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,
cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl- containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R0 and R2 through R11 may be further independently selected from amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
haloalkyl, cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties of the formula
-YnA wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from w wherein each W is independently selected from oxygen atom, sulfur atom and NR39; wherein each of R35, R38 and R39 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R33 and R39 may be further independently selected from amino radical of the formula
wherein each of R40 and R41 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially
unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from R3 through R11 so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R0 through R26, R35 and R38 through R41, Y and A and independently may be substituted at any
substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,
alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
68. The method of Claim 67 wherein m is one; wherein R1 is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, thienylalkyl, phenylalkyl, polycycloalkyl, polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl,
aralkylcarbonyl, alkenyl and alkynyl; where each of R0 and R2 is independently selected from hydrido, alkyl, aminoalkyl, hydroxyalkyl, formyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,
thienylalkyl, phenylalkyl, polycycloalkyl,
polycycloalkylalkyl, phenyl, halophenyl, alkylphenyl, alkoxyphenyl, cycloalkenyl, cycloalkenylalkyl,
aralkylhaloalkyl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,
alkylcarbonyl, alkylcarbonyloxy, mercaptoalkyl,
mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,
aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula
wherein X is selected from oxygen atom and sulfur atom; wherein each n is a number independently selected from zero to six, inclusive; wherein each of R14 through R26 is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,
hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R3 through R11 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R0 and R3 through R11 may be further independently selected from acidic moieties consisting of CO2H, CO2CH3, SH, CH2SH, C2H4SH, PO3H2, NHSO2CF3,
NHSO2C6F5, SO3H, CONHNH2, CONHNHSO2CF3, CONHOCH3,
CONHOC2H5, CONHCF3, OH, CH2OH, C2H4OH, OPO3H2, OSO3H,
wherein each of R42, R43 and R44 is independently selected from H, Cl, CN, NO2, CF3, C2F5, C3F7, CHF2, CH2F, CO2CH3, CO2C2H5, SO2CH3, SO2CF3 and SO2C5F5; wherein Z is selected from O, S, NR43 and CH2; wherein R43 is selected from hydrido, CH3 and CH2C5H5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R3 through R11 so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from
and the esters, amides and salts of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
69. The method of Claim 68 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl. methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R13 is selected from hydrido,
C4H9(n), CH3CH2CH=CH, C3H7(n) , SC3H7,
, C2H5, C5H11(n), C6H13(n), SC4H9, ,
CH3CH=CH, CH3CH2CH2CH=CH-, amino, aminomethyl, aminoethyl, aminopropyl, CH2OH, CH2OCOCH3, CH2CI, CH2OCH3, CH2OCH(CH3)2, CHO,
CH2CO2H, CH(CH3)CO2H, NO2, Cl,
-CO2CH3, -CONH2, -CONHCH3, CON(CH3)2,
-CH2-NHCO2C2H5,
, -CH2NHCO2CH3,-CH2NHCO2C3H7, -CH2NHCO2CH2(CH3)2, -CH2NHCO2C4H9, CH2NHCO2-adamantyl,
-CH2NHCO2-d-napthyl), -CH2NHCONHCH3, -CH2NHCONHC2H5,
-CH2NHCONHC3H7, -CH2NHCONHC4H9, -CH2NHCONHCH(CH3)2,
-CH2NHCONH(1-napthyl), -CH2NHCONH(1-adamantyl), , , -CH2CH2CH2CO2H,
-CH2CH2F, -CH2OCONHCH3, -CH2OCSNHCH3, -CH2NHCSOC3H7,
-CH2CH2CH2F, -CH2ONO2, , -CH2SH,
,
Cl, NO2, CF3, CH2OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, cyclohexyl,
cyclohexylmethyl, carboxyl, formyl, 1-oxoethyl,
1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,
1,1-difluoro-2-phenylethyl, monofluoromethyl,
1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,
1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,
1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, difluoromethyl, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
70. The method of Claim 69 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n- pentyl, neopentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1- oxopentyl 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl,
1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,
cyclohexylethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio, butylthio, CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3,
OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, propylthio. butylthio and hydroxyalkyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5, R6, R8 and R9 is an acidic group selected from CO2H, SH, PO3H2 SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
71. The method of Claim 70 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl, dimethoxymethyl,
1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, dimethoxymethyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,
neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R3 and R9 is an acidic group selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3,
OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
72. The method of Claim 71 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl. cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; with the proviso that at least one of R5 and R9 must be selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH,
wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
73. The method of Claim 72 wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl
cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, propylthio,
butylthio and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R10 and R11 is hydrido; wherein one of R5 and R9 is hydrido and the other of R3 and R9 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof .
74. The method of Claim 73 wherein said active compound is selected from a family of compounds of Formula II
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CI2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
75. The method of Claim 74 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, .
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
76. The method of Claim 75 wherein said active compound is selected from compounds and their
pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one; 1,4-dibutyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H-tetrazol-5- yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5- [2-(1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[5-[2- (1H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol- 2-one.
77. The method of Claim 73 wherein said active compound is selected from a family of compounds of Formula III
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl. cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
78. The method of Claim 77 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
79. The method of Claim 78 wherein said active compound is selected from compounds and their
pharmaceutically-acceptable salts of the group of compounds consisting of
1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1,4-dipropyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-propyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-isobutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-isopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-pentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-cyclohexyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-butyl-4-cyclopentyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinylJmethyl]-2H-imidazol-2-one;
1-butyl-4-(2-cyclopropylethyl)-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-methyl-4-butyl-l,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-ethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinylJmethyl]-2H-imidazol-2-one;
1-propyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-isobutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-isopropyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-tertbutyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-neopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3- pyridinyl]methyl]-2H-imidazol-2-one;
1-(3,3-dimethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl] 3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]- 3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclopropylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yDphenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-cyclopentylmethyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-[2-(2-thienyl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-cyclopentylethyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-[2-(cyclopenten-1-yl)ethyl]-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(1-adamantyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-phenyl-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-chlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; 1- (2-methyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-methoxyphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2-isopropyIphenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2,6-difluorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one;
1-(2,6-dichlorophenyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one; and
1- (2, 6-dimethylphenyl ) -4-butyl-1, 3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H-imidazol-2-one .
80. The method of Claim 73 wherein said active compound is selected from a family of compounds of Formula IV
wherein R1 is selected from methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl,
cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethyIphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
81. The method of Claim 80 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
82. The method of Claim 81 wherein said active compound is selected from compounds and their pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2- pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5- yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1, 4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-phenylmethyl-4-butyl-5-methyl-1, 3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one.
83. The method of Claim 73 wherein said active compound is selected from a family of compounds of Formula v
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl. adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R3 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
84. The method of Claim 83 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
85. The method of Claim 84 wherein said active compound is selected from compounds and their
pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl) -3-pyridinyl] phenyl ] methyl ] -2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1, 3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1- (2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3- [ [4- [4 - (1H-tetrazol-5-yl) -3-pyridinyl] phenyl]methyl] -2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4- [4-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[4- (1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
86. The method of Claim 73 wherein said active compound is selected from a family of compounds of Formula VI
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2- cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
87. The method of Claim 86 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
88. The method of Claim 87 wherein said active compound is selected from compounds and their
pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2--one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl) -4-pyridinyl ] phenyl] methyl ] -2H-imidazol-2-one;
1, 4-dibutyl-5-methyl-1,3-dihydro-3- [ [ 4- [3- (1H-tetrazol-5 -yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4- [3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3- (1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[3-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
89. The method of Claim 73 wherein said active compound is selected from a family of compounds of Formula VII
wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,
cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro,
monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R5 is an acidic group selected from CO2H and
or a. tautomer thereof or a pharmaceutically-acceptable salt thereof.
90. The method of Claim 89 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl,
methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl, cyclopentenylmethyl,
cyclopentenylethyl, cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl,
adamantylmethyl, adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl,
methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl,
diethylphenyl, benzyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methylbutyl, ethylbutyl, dimethylbutyl, thienylmethyl, thienylethyl, thienylpropyl,
cyclopentenylmethyl, cyclopentenylethyl,
cyclopentenylpropyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, adamantyl, adamantylmethyl,
adamantylethyl, phenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methoxyphenyl, ethoxyphenyl, methylphenyl, ethylphenyl, propylphenyl, isopropylphenyl, dimethylphenyl, diethylphenyl and benzyl; wherein R3 is an acidic group selected from CO2H and
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
91. The method of Claim 90 wherein said active compound is selected from compounds and their
pharmaceutically-acceptable salts of the group of compounds consisting of
1-propyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1,4-dibutyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1-cyclohexylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-phenylmethyl-4-butyl-1,3-dihydro-3-[[4-[2-(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-(2-phenylethyl)-4-butyl-1,3-dihydro-3-[[4-[2-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-propyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1,4-dibutyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5- yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one;
1-isopentyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-phenylmethyl-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-(2-phenylethyl)-4-butyl-5-methyl-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-propyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one; 1, 4-dibutyl-5-chloro-1,3-dihydro-3- [ [4- [-2 (1H-tetrazol-5 -yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-pentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-isopentyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-cyclohexylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one;
1-phenylmethyl-4-butyl-5-chloro-1,3-dihydro-3-[[4-[-2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one;
1-(2-cyclohexylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol- 2-one; and
1-(2-phenylethyl)-4-butyl-5-chloro-1,3-dihydro-3-[[4-[- 2(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2-one.
92. The method of Claim 79 wherein said active compound is 1,4-dibutyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof.
93. The method of Claim 79 wherein said active compound is
1-(2-ethylbutyl)-4-butyl-1,3-dihydro-3-[[6-[2-(1H-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one
or a pharmaceutically-acceptable salt thereof.
94. The method of Claim 63 wherein said circulatory disorder is a cardiovascular disorder.
95. The method of Claim 94 wherein said cardiovascular disorder is hypertension.
96. The method of Claim 94 wherein said cardiovascular disorder is congestive heart failure.
EP92911354A 1991-04-05 1992-04-01 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders Expired - Lifetime EP0579766B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US681011 1991-04-05
US07/681,011 US5164403A (en) 1991-04-05 1991-04-05 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
PCT/US1992/002439 WO1992017469A2 (en) 1991-04-05 1992-04-01 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders

Publications (2)

Publication Number Publication Date
EP0579766A1 true EP0579766A1 (en) 1994-01-26
EP0579766B1 EP0579766B1 (en) 1999-06-02

Family

ID=24733424

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92911354A Expired - Lifetime EP0579766B1 (en) 1991-04-05 1992-04-01 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
EP92106050A Expired - Lifetime EP0508393B1 (en) 1991-04-05 1992-04-06 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP92106050A Expired - Lifetime EP0508393B1 (en) 1991-04-05 1992-04-06 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders

Country Status (11)

Country Link
US (4) US5164403A (en)
EP (2) EP0579766B1 (en)
AT (1) ATE180779T1 (en)
AU (1) AU1927892A (en)
CA (1) CA2104794A1 (en)
DE (1) DE69229341T2 (en)
DK (1) DK0579766T3 (en)
ES (1) ES2133142T3 (en)
GR (1) GR3030892T3 (en)
IE (2) IE921079A1 (en)
WO (1) WO1992017469A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5861420A (en) * 1991-04-05 1999-01-19 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
DE69233734D1 (en) * 1991-11-18 2008-06-26 Du Pont 2- (2'-Triphenylmethyl-2'H-tetrazol-5'-yl) phenylboronic acid as an intermediate for the synthesis of A II receptor antagonists
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
JPH08502285A (en) * 1992-10-13 1996-03-12 ジー．ディー．サール アンド カンパニー N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treating cardiovascular disorders
DE69328108D1 (en) * 1992-10-13 2000-04-20 Searle & Co N-ARYLHETEROARYLALKYL-1-PHENYL-IMIDAZOL-2-ON COMPOUNDS IN THE TREATMENT OF CIRCULATORY DISORDERS
EP0690854B1 (en) * 1993-03-24 2000-07-12 G.D. Searle & Co. 1-phenyl-imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders
DE4316077A1 (en) * 1993-05-13 1994-11-17 Bayer Ag Substituted mono- and bihydridylmethylpyridones
DE4320432A1 (en) * 1993-06-21 1994-12-22 Bayer Ag Substituted mono- and bipyridylmethyl derivatives
US5780492A (en) * 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2276081A1 (en) * 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibitors of farnesyl-protein transferase
US6093737A (en) * 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
US7358269B2 (en) * 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
ES2281312T3 (en) 2003-01-16 2008-08-01 Teva Pharmaceutical Industries Ltd. NEW SYNTHESIS OF IRBESARTAN.
KR20110077006A (en) 2006-08-15 2011-07-06 노파르티스 아게 Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
EP2308851A1 (en) 2006-10-19 2011-04-13 F. Hoffmann-La Roche AG Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE621842A (en) * 1962-08-27
IT1052119B (en) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti TRIAZOLINONE DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
EP0007180B1 (en) * 1978-06-15 1983-03-30 Beecham Group Plc Prostaglandin analogue triazole derivatives, processes for their preparation and a pharmaceutical composition containing them
DD160447A1 (en) * 1981-03-26 1983-08-03 Johannes Dost HERBICIDAL AGENTS CONTAINING 1,2,4-TRIAZOLINONE- (5)
IL69407A (en) * 1982-08-23 1987-10-20 Warner Lambert Co 2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
US4600430A (en) * 1985-02-22 1986-07-15 Eli Lilly And Company Pyridinylimidazolidinone compounds
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
US5218677A (en) * 1989-05-30 1993-06-08 International Business Machines Corporation Computer system high speed link method and means
US5164407A (en) * 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE69024556T2 (en) * 1989-07-28 1996-10-17 Merck & Co Inc Substituted triazolinones, triazolinthiones and triazolinimines as angiotensin II antagonists
ATE113281T1 (en) * 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND APPLICATION.
WO1991018888A1 (en) * 1990-05-25 1991-12-12 G.D. Searle & Co. N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
GB9019839D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9217469A3 *

Also Published As

Publication number Publication date
ES2133142T3 (en) 1999-09-01
US5643906A (en) 1997-07-01
US5451592A (en) 1995-09-19
GR3030892T3 (en) 1999-11-30
US5441970A (en) 1995-08-15
US5164403A (en) 1992-11-17
EP0579766B1 (en) 1999-06-02
DE69229341T2 (en) 1999-10-14
IE921095A1 (en) 1992-10-07
AU1927892A (en) 1992-11-02
ATE180779T1 (en) 1999-06-15
WO1992017469A3 (en) 1992-11-12
CA2104794A1 (en) 1992-10-06
DK0579766T3 (en) 1999-06-23
WO1992017469A2 (en) 1992-10-15
DE69229341D1 (en) 1999-07-08
IE921079A1 (en) 1992-10-07
EP0508393B1 (en) 1999-06-02
EP0508393A1 (en) 1992-10-14

Similar Documents

Publication Publication Date Title
EP0508393B1 (en) N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US6090828A (en) 5-aryleheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5087634A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5602153A (en) Method of using 1-arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of a giaucoma disorder
US5187271A (en) N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders
US6492397B1 (en) N-arylheteroarylalkyl imidazol-2-one compounds for treatment of arteriosclerosis
US5451597A (en) Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
EP0664802B1 (en) N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds for treatment of circulatory disorders
US5238952A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
WO1994008989A1 (en) N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treatment of circulatory disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960702

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990602

REF Corresponds to:

Ref document number: 180779

Country of ref document: AT

Date of ref document: 19990615

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: DIETLIN & CIE S.A.

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69229341

Country of ref document: DE

Date of ref document: 19990708

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2133142

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000401

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000401

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000401

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000403

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

26N No opposition filed
BERE Be: lapsed

Owner name: G.D. SEARLE & CO.

Effective date: 20000430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000401

EUG Se: european patent has lapsed

Ref document number: 92911354.6

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20001101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20020304

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050401